<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">82050</article-id><article-id pub-id-type="doi">10.7554/eLife.82050</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses can originate from cross-reactive CMV-specific T cells</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-286992"><name><surname>Pothast</surname><given-names>Cilia R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9761-3123</contrib-id><email>c.r.pothast@lumc.nl</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287861"><name><surname>Dijkland</surname><given-names>Romy C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3479-9303</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-180922"><name><surname>Thaler</surname><given-names>Melissa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5590-4918</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287862"><name><surname>Hagedoorn</surname><given-names>Renate S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287863"><name><surname>Kester</surname><given-names>Michel GD</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8960-7348</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287864"><name><surname>Wouters</surname><given-names>Anne K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-157000"><name><surname>Hiemstra</surname><given-names>Pieter S</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287878"><name><surname>van Hemert</surname><given-names>Martijn J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2617-9243</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-238436"><name><surname>Gras</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287879"><name><surname>Falkenburg</surname><given-names>JH Frederik</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287880"><name><surname>Heemskerk</surname><given-names>Mirjam HM</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6320-9133</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05xvt9f17</institution-id><institution>Department of Hematology, Leiden University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Leiden</named-content></addr-line><country>Netherlands</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05xvt9f17</institution-id><institution>Department of Medical Microbiology, Leiden University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Leiden</named-content></addr-line><country>Netherlands</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05xvt9f17</institution-id><institution>Department of Pulmonology, Leiden University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Leiden</named-content></addr-line><country>Netherlands</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01rxfrp27</institution-id><institution>Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University</institution></institution-wrap><addr-line><named-content content-type="city">Victoria</named-content></addr-line><country>Australia</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02bfwt286</institution-id><institution>Department of Biochemistry and Molecular Biology, Monash University</institution></institution-wrap><addr-line><named-content content-type="city">Clayton</named-content></addr-line><country>Australia</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Belz</surname><given-names>Gabrielle T</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rqy9422</institution-id><institution>University of Queensland</institution></institution-wrap><country>Australia</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rath</surname><given-names>Satyajit</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02r2k1c68</institution-id><institution>Indian Institute of Science Education and Research (IISER)</institution></institution-wrap><country>India</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>21</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e82050</elocation-id><history><date date-type="received" iso-8601-date="2022-07-21"><day>21</day><month>07</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-11-13"><day>13</day><month>11</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-08-01"><day>01</day><month>08</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.07.31.502203"/></event></pub-history><permissions><copyright-statement>© 2022, Pothast et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Pothast et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-82050-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-82050-figures-v2.pdf"/><related-article related-article-type="commentary" ext-link-type="doi" xlink:href="10.7554/eLife.85080" id="ra1"/><abstract><p>Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells in SARS-CoV-2-unexposed donors has been explained by the presence of T cells primed by other coronaviruses. However, based on the relatively high frequency and prevalence of cross-reactive T cells, we hypothesized cytomegalovirus (CMV) may induce these cross-reactive T cells. Stimulation of pre-pandemic cryo-preserved peripheral blood mononuclear cells (PBMCs) with SARS-CoV-2 peptides revealed that frequencies of SARS-CoV-2-specific T cells were higher in CMV-seropositive donors. Characterization of these T cells demonstrated that membrane-specific CD4<sup>+</sup> and spike-specific CD8<sup>+</sup> T cells originate from cross-reactive CMV-specific T cells. Spike-specific CD8<sup>+</sup> T cells recognize SARS-CoV-2 spike peptide FVSNGTHWF (FVS) and dissimilar CMV pp65 peptide IPSINVHHY (IPS) presented by HLA-B*35:01. These dual IPS/FVS-reactive CD8<sup>+</sup> T cells were found in multiple donors as well as severe COVID-19 patients and shared a common T cell receptor (TCR), illustrating that IPS/FVS-cross-reactivity is caused by a public TCR. In conclusion, CMV-specific T cells cross-react with SARS-CoV-2, despite low sequence homology between the two viruses, and may contribute to the pre-existing immunity against SARS-CoV-2.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>heterologous immunity</kwd><kwd>cross-reactivity</kwd><kwd>T cells</kwd><kwd>CMV</kwd><kwd>SARS-CoV-2</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Health~Holland</institution></institution-wrap></funding-source><award-id>LSHM19088</award-id><principal-award-recipient><name><surname>Heemskerk</surname><given-names>Mirjam HM</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>1159272</award-id><principal-award-recipient><name><surname>Gras</surname><given-names>Stephanie</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Gras</surname><given-names>Stephanie</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Insight into pre-existing SARS-CoV-2-specific T cell responses caused by heterologous T cell immunity directed against dissimilar epitopes, mediated by a public T cell receptor.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The effectiveness of the innate and adaptive immune system is an important factor for disease outcome during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; <xref ref-type="bibr" rid="bib12">Brodin, 2021</xref>). CD4<sup>+</sup> and CD8<sup>+</sup> T cells are important components of the adaptive immune system as CD4<sup>+</sup> T cells promote antibody production by B cells and help cytotoxic CD8<sup>+</sup> T cells to mediate cytotoxic lysis of SARS-CoV-2 infected cells (<xref ref-type="bibr" rid="bib59">Sette and Crotty, 2021</xref>). Whilst immunity is commonly measured solely based on antibody titers, research into coronavirus disease 2019 (COVID-19) pathophysiology and vaccination effectiveness has associated an effective T cell response with less severe COVID-19 (<xref ref-type="bibr" rid="bib6">Bange et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Bertoletti et al., 2021</xref>; <xref ref-type="bibr" rid="bib36">Liao et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Rydyznski Moderbacher et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Sekine et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">Sette and Crotty, 2021</xref>; <xref ref-type="bibr" rid="bib67">Tan et al., 2021a</xref>). Additionally, SARS-CoV-2-specific T cell responses have been shown to be present in most individuals 6 months after infection or vaccination and remain largely unaffected by emerging variants of concern, illustrating their importance in generating durable immune responses (<xref ref-type="bibr" rid="bib14">Chiuppesi et al., 2022</xref>; <xref ref-type="bibr" rid="bib15">Choi et al., 2022</xref>; <xref ref-type="bibr" rid="bib22">Gao et al., 2022</xref>; <xref ref-type="bibr" rid="bib23">GeurtsvanKessel et al., 2022</xref>; <xref ref-type="bibr" rid="bib29">Jung et al., 2022</xref>; <xref ref-type="bibr" rid="bib30">Keeton et al., 2022</xref>; <xref ref-type="bibr" rid="bib38">Liu et al., 2022</xref>; <xref ref-type="bibr" rid="bib52">Redd et al., 2022</xref>; <xref ref-type="bibr" rid="bib70">Tarke et al., 2022</xref>).</p><p>Besides de novo SARS-CoV-2-specific T cell responses in infected individuals, SARS-CoV-2-specific T cells have also been identified in unexposed individuals (<xref ref-type="bibr" rid="bib24">Grifoni et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Mateus et al., 2020</xref>; <xref ref-type="bibr" rid="bib44">Nelde et al., 2021</xref>; <xref ref-type="bibr" rid="bib72">Weiskopf et al., 2020</xref>). This finding indicates that T cells which were initially primed against other pathogens are able to cross-recognize SARS-CoV-2 antigen. This phenomenon is called heterologous immunity and can often be explained by genomic sequence homology between pathogens. Highly homologous DNA sequences are translated into similar proteins which can be processed and presented as epitopes with high sequence similarity in human leukocyte antigen (HLA). For this reason, most research has focused on cross-reactive T cells that are potentially primed by other human coronaviruses (HCoVs) since they share around 30% amino acid sequence homology with SARS-CoV-2 (<xref ref-type="bibr" rid="bib5">Bacher et al., 2020</xref>; <xref ref-type="bibr" rid="bib11">Braun et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Johansson et al., 2021</xref>; <xref ref-type="bibr" rid="bib33">Kundu et al., 2022</xref>; <xref ref-type="bibr" rid="bib34">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Loyal et al., 2021</xref>; <xref ref-type="bibr" rid="bib41">Mateus et al., 2020</xref>). However, it has been postulated that SARS-CoV-2-specific T cells in unexposed individuals could also conceivably be primed by other, non-HCoVs (<xref ref-type="bibr" rid="bib34">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Peng et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Stervbo et al., 2020</xref>; <xref ref-type="bibr" rid="bib68">Tan et al., 2021b</xref>). Furthermore, previous studies, although limited, have demonstrated the occurrence of cross-reactivity between two epitopes with relatively low sequence homology (<xref ref-type="bibr" rid="bib8">Bijen et al., 2018</xref>; <xref ref-type="bibr" rid="bib13">Cameron et al., 2013</xref>; <xref ref-type="bibr" rid="bib16">Clute et al., 2005</xref>; <xref ref-type="bibr" rid="bib18">Cornberg et al., 2010</xref>; <xref ref-type="bibr" rid="bib53">Riley et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Su and Davis, 2013</xref>). This form of heterologous immunity is poorly understood, and therefore, predicting such cross-reactivity remains a challenge (<xref ref-type="bibr" rid="bib35">Lee et al., 2020</xref>).</p><p>Pre-pandemic SARS-CoV-2-specific T cells are reportedly present in a relatively high proportion of the population, independent of geographical location, indicating that a highly prevalent pathogen could be the initial trigger of these cross-reactive T cells (<xref ref-type="bibr" rid="bib11">Braun et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Grifoni et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Mateus et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Meckiff et al., 2020</xref>; <xref ref-type="bibr" rid="bib44">Nelde et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Sekine et al., 2020</xref>; <xref ref-type="bibr" rid="bib72">Weiskopf et al., 2020</xref>). Furthermore, these cross-reactive T cells should be present in relatively high frequencies, as they are detectable in antigen-induced stimulation assays without additional amplification steps (<xref ref-type="bibr" rid="bib11">Braun et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Grifoni et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Sekine et al., 2020</xref>; <xref ref-type="bibr" rid="bib72">Weiskopf et al., 2020</xref>). Cytomegalovirus (CMV) is a highly prevalent pathogen and usually induces high T cell frequencies, making CMV a potential trigger for cross-reactive SARS-CoV-2-specific T cells (<xref ref-type="bibr" rid="bib64">Sylwester et al., 2005</xref>; <xref ref-type="bibr" rid="bib75">Zuhair et al., 2019</xref>). This is supported by the finding that SARS-CoV-2 cross-reactive CD8<sup>+</sup> T cells were increased in CMV-seropositive (CMV<sup>+</sup>) donors and that previous CMV infection has been associated with severe COVID-19 (<xref ref-type="bibr" rid="bib3">Alanio et al., 2022</xref>; <xref ref-type="bibr" rid="bib27">Jo et al., 2021</xref>; <xref ref-type="bibr" rid="bib71">Weber et al., 2022</xref>). Studies so far indicate that cross-reactive T cells can play a role in COVID-19 immunity, but whether they are protective or pathogenic is unclear (<xref ref-type="bibr" rid="bib5">Bacher et al., 2020</xref>; <xref ref-type="bibr" rid="bib33">Kundu et al., 2022</xref>). Taken together, we hypothesized that cross-reactive SARS-CoV-2-specific T cells might originate from the CMV-specific memory population.</p><p>In the present study, we aimed to identify SARS-CoV-2-specific cross-reactive CD4<sup>+</sup> and CD8<sup>+</sup> T cells in SARS-CoV-2-unexposed individuals. We found an increased presence of cross-reactive T cells in CMV<sup>+</sup> donors, and upon isolation and clonal expansion of the spike-reactive CD8<sup>+</sup> and membrane-reactive CD4<sup>+</sup> T cells, we confirmed that these T cells were reactive against both SARS-CoV-2 and CMV. Interestingly, isolated CD8<sup>+</sup> T cells recognizing a previously described CMV epitope IPSINVHHY presented by HLA-B*35:01 were cross-reactive with dissimilar SARS-CoV-2 spike peptide FVSNGTHWF presented by HLA-B*35:01, demonstrating that cross-reactivity does not solely depend on peptide sequence homology. The T cell receptor (TCR) isolated from these CD8<sup>+</sup> T cells was found in multiple donors showing that pre-pandemic spike-reactive CD8<sup>+</sup> T cells can be caused by a public CMV-specific TCR. Based on the reduced activation status compared to other SARS-CoV-2-specific T cells in severe COVID-19 patients, we hypothesize that these cross-reactive T cells are not important for clearing the virus at this late stage of the disease. However, these cross-reactive CD8<sup>+</sup> T cells were shown to reduce spreading of SARS-CoV-2 infection in vitro, and in two out of two CMV<sup>+</sup> severe COVID-19 patients, these cross-reactive T cells were detected. This indicates that early in infection at the stage that no SARS-CoV-2-specific T cells are present yet, and these cross-reactive T cells may play a role in preventing SARS-CoV-2 infection or reducing the severity of COVID-19.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>SARS-CoV-2-specific T cell responses in SARS-CoV-2-unexposed PBMCs correlate with CMV seropositivity</title><p>To investigate whether SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses in SARS-CoV-2-unexposed donors correlate with previous CMV infection, pre-pandemic cryopreserved PBMCs from CMV seropositive (CMV<sup>+</sup>, N=28) and CMV seronegative (CMV<sup>−</sup>, N=39) healthy individuals were stimulated overnight using SARS-CoV-2 15-mer peptide pools. These pools included three spike peptide pools that together overlap the entire spike gene (S, S1, and S+), membrane (M), and nucleocapsid (N) antigens from SARS-CoV-2. To confirm that CMV<sup>+</sup> individuals have CMV-specific T cells, reactivity against the most immunogenic CMV antigen, pp65, was also tested. Memory SARS-CoV-2-specific CD4<sup>+</sup> T cells were characterized as CD154<sup>+</sup>CD137<sup>+</sup>, and memory SARS-CoV-2-specific CD8<sup>+</sup> T cells were identified based on expression of CD137 and IFN-γ (<xref ref-type="fig" rid="fig1">Figure 1A–B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). As expected, all CMV<sup>+</sup> donors displayed a CD4<sup>+</sup> and/or CD8<sup>+</sup> T cell response upon stimulation with pp65 (<xref ref-type="fig" rid="fig1">Figure 1C–E</xref>). No marked increase of CD4<sup>+</sup> T cell responses was observed after SARS-CoV-2 spike and nucleocapsid stimulation in the CMV<sup>+</sup> group compared to CMV<sup>−</sup>. However, six donors in the CMV<sup>+</sup> group displayed a CD4<sup>+</sup> T cell response against the membrane peptide pool which was not observed in the CMV<sup>−</sup> group (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Furthermore, CD4<sup>+</sup> T cell response against the membrane pool was accompanied by a CD4<sup>+</sup> T cell response against pp65 (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). In addition, CD8<sup>+</sup> T cell responses were detected against spike peptides in two CMV<sup>+</sup> donors which were not detected in CMV<sup>−</sup> donors (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Interestingly, donors with a high CD8<sup>+</sup> T cell response against SARS-CoV-2 spike peptides additionally displayed strong reactivity against pp65 (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Taken together, these results show that SARS-CoV-2-unexposed CMV<sup>+</sup>, but not CMV<sup>−</sup>, individuals had detectable CD4<sup>+</sup> T cell responses against membrane peptides and CD8<sup>+</sup> T cells targeting spike peptides. These SARS-CoV-2 responses were accompanied by T cell responses against pp65 and thus may indicate that SARS-CoV-2 T cell responses in pre-pandemic samples potentially are memory T cells targeting pp65.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Ex vivo severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses in cytomegalovirus (CMV)-positive and -negative unexposed donors.</title><p>Pre-pandemic cryo-preserved PBMCs were stimulated using SARS-CoV-2 spike (S, S1, and S+), membrane (M), nucleocapsid (N), and CMV pp65 peptide pools or not stimulated (dimethylsulfoxide; DMSO). (<bold>A</bold>) A representative flow cytometry example of a CD4<sup>+</sup> T cell response in a SARS-CoV-2-unexposed donor. Numbers in plot represent frequencies of CD137<sup>+</sup>CD154<sup>+</sup> cells of total CD4<sup>+</sup> T cells. (<bold>B</bold>) A representative flow cytometry example of a CD8<sup>+</sup> T cell response in a SARS-CoV-2-unexposed donor. Numbers in plot represent frequencies of CD137<sup>+</sup>IFN-γ<sup>+</sup> cells of total CD8<sup>+</sup> T cells. (<bold>C</bold>) Scatter plot showing frequencies of CD137<sup>+</sup>CD154<sup>+</sup> cells of total CD4<sup>+</sup> T cells of CMV<sup>+</sup> (green, N=28) and CMV<sup>−</sup> (gray, N=39) donors. (<bold>D</bold>) Frequencies of CD137<sup>+</sup>CD154<sup>+</sup> cells of total CD4<sup>+</sup> T cells in the membrane-stimulated condition (membrane response) plotted against pp65-stimulated condition (pp65 response). Three letter codes are anonymized codes of CMV<sup>+</sup> (green) and CMV<sup>−</sup> (gray) donors. (<bold>E</bold>) Scatter plot showing frequencies of CD137<sup>+</sup> IFN-γ<sup>+</sup> cells of total CD8<sup>+</sup> T cells of CMV<sup>+</sup> (green, N=28) and CMV<sup>−</sup> (gray, N=39) donors. (<bold>F</bold>) Frequencies of CD137<sup>+</sup>IFN-γ<sup>+</sup> cells of total CD8<sup>+</sup> T cells in the spike-stimulated condition (spike response) plotted against pp65-stimulated condition (pp65 response).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source data containing the percentages underlying <xref ref-type="fig" rid="fig1">Figure 1C–F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-82050-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82050-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Flow cytometry gating example for peptide stimulation assays.</title><p>Representative example of flow cytometry gating strategy for peptide-reactive CD4<sup>+</sup> and CD8<sup>+</sup> T cells. All events were gated on lymphocytes, single cells, viable cells, CD14 and CD19 negative, and either CD4 or CD8 positive. For CD4<sup>+</sup> T cells, activation was measured by upregulation of CD137 and CD154 compared to DMSO. For CD8<sup>+</sup> T cells, activation was measured by upregulation of CD137 and IFN-γ production compared to DMSO.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82050-fig1-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Pre-pandemic SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells recognize pp65 peptides from CMV</title><p>To confirm that pre-pandemic SARS-CoV-2-specific T cells are able to recognize peptides from pp65, these SARS-CoV-2-specific T cells were isolated and clonally expanded. SARS-CoV-2-unexposed (pre-pandemic cryopreserved) PBMCs from a CMV<sup>+</sup> individual showing a CD4<sup>+</sup> T cell response against SARS-CoV-2 membrane protein (donor UGT) were stimulated with the membrane peptide pool and single cell sorted based on CD137 upregulation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). After clonal expansion, 20 out of 27 screened T cell clones produced IFN-γ when stimulated with membrane peptide pool compared to no peptide stimulation (data not shown). T cell clones 4UGT5, 4UGT8, and 4UGT17, all three expressing a different TCR, were used for further experiments (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). As hypothesized, the T cell clones were reactive against both SARS-CoV-2 membrane antigen and CMV pp65 when loaded on HLA-matched EBV-lymphoblastoid cell lines (EBV-LCLs; <xref ref-type="fig" rid="fig2">Figure 2A</xref>). Interestingly, IFN-γ production by the T cell clones was significantly increased when stimulated with pp65 peptides compared to membrane peptides, indicating higher avidity for CMV compared to SARS-CoV-2 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). To identify which peptide in pp65 is recognized, reactivity of T cell clone 4UGT8 against a pp65 library was measured which resulted in recognition of three sub pools which contained peptide AGILARNLVPM (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B–C</xref>). HLA-mismatched EBV-LCLs were retrovirally transduced with HLA Class II molecules that were commonly shared between donors that had a detectable CD4<sup>+</sup> T cell response against the membrane and pp65 peptide pool (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). T cell clone 4UGT8 recognized both peptide pools and the AGI peptide only when presented in HLA-DRB3*02:02 (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>). The SARS-CoV-2 membrane protein epitope recognized by these cross-reactive T cells remains unidentified as in vitro experiments and in silico prediction methods failed to identify the epitope. A similar approach was applied for CD8<sup>+</sup> T cells in which T cell clones were generated after SARS-CoV-2 spike peptide pool stimulation of PBMCs from CMV<sup>+</sup> donor UTT (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). The isolated CD8<sup>+</sup> T cell clones were screened for their reactivity with SARS-CoV-2 spike which showed that 23 out of the 28 T cell clones produced IFN-γ upon spike peptide pool stimulation (data not shown). TCR sequencing revealed that all 23T cell clones expressed the same TCR (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>). T cell clone 8UTT6 was selected for further testing and analyzed for its cross reactivity toward SARS-CoV-2 spike and CMV pp65 peptide pools. Additionally, the HLA restriction of T cell clone 8UTT6 was hypothesized to be HLA-B*35:01 as the unexposed donors with a CD8<sup>+</sup> T cell response against SARS-CoV-2 spike (UTT and UBV) both expressed HLA-B*35:01. The results confirmed that T cell clone 8UTT6 recognized spike as well as pp65 peptide pool presented by K562 cells transduced with HLA-B*35:01 but not transduced with HLA-A*11:01 (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). To identify the spike epitope, reactivity of clone 8UTT6 against the 15-mer spike peptide library was measured. For the identification of the CMV epitope, an unbiased approach was performed using the nonamer combinatorial peptide library (CPL) assay. Recognition patterns were analyzed using netMHC 4.0 analysis for predicted binding to HLA-B*35:01, which revealed SARS-CoV-2 spike peptide FVSNGTHWF (FVS, S<sub>1094–1103</sub>) and CMV pp65 IPSINVHHY (IPS, pp65<sub>112-121</sub>) as the most likely epitopes (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B–E</xref>). The FVS and IPS peptides were indeed recognized by clone 8UTT6 (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Importantly, the IPS peptide was recognized with higher avidity compared to the FVS peptide by clone 8UTT6 (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Supporting these findings, the same TCRβ chain was already described and demonstrated to be specific for IPS in HLA-B*35:01 (<xref ref-type="bibr" rid="bib31">Klarenbeek et al., 2012</xref>). Taken together, SARS-CoV-2 reactive CD4<sup>+</sup> and CD8<sup>+</sup> T cells in pre-pandemic samples cross reacted with CMV and SARS-CoV-2 peptides.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Recognition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cytomegalovirus (CMV) by pre-existing CD4<sup>+</sup> and CD8<sup>+</sup> T cells.</title><p>Clonally expanded CD4<sup>+</sup> T cells from donor UGT and CD8<sup>+</sup> T cells from donor UTT were overnight co-cultured with peptide-pulsed stimulator cells. (<bold>A–B</bold>) Percentages of CD154<sup>+</sup>, CD137<sup>+</sup>, and/or IFN-γ<sup>+</sup> cells of cross-reactive CD4<sup>+</sup> T cell clones after overnight culture (T only) or after overnight co-culture with HLA-matched EBV-lymphoblastoid cell lines (EBV-LCLs) that were not peptide pulsed (x) or loaded with membrane (M) or pp65 peptide pool, measured by flow cytometry. Dots represent the mean of experimental repeats of 4UGT5 (square, one repeat), 4UGT8 (circles, four repeats), and 4UGT17 (triangle, two repeats). Significance was tested by a paired <italic>t</italic>-test. (<bold>C</bold>) Bar graphs showing ELISA measurement of secreted IFN-γ after co-culturing of a representative clone, 4UGT8 clone, with HLA-matched or HLA-mismatched EBV-LCLs. HLA-mismatched EBV-LCLs were retrovirally transduced with HLA class II molecule as depicted in figure. Stimulator cells were peptide-pulsed with membrane (M) peptide pool, pp65 peptide pool, or AGILARNLVPM (AGI) peptide. Data points are experimental duplicates. Black arrows indicate that values were above plateau value of the ELISA calibration curve. (<bold>D–E</bold>) Bar graphs showing ELISA measurement of secreted IFN-γ after co-culturing of a representative clone, 8UTT6 clone, with HLA-matched EBV-LCLs or K562s transduced with HLA-B*35:01 or HLA-A*11:01. Stimulator cells were peptide-pulsed with spike (S) peptide pool, pp65 peptide pool, IPSINVHHY (IPS) peptide, or FVSNGTHWF (FVS) peptide. Data points are technical triplicates. (<bold>F</bold>) Peptide titration of IPS peptide (blue) and FVS peptide (purple) in a co-culture assay with 8UTT6 clone.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82050-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Flow-activated cell sorting gating example for peptide stimulation assays.</title><p>Representative example of fluorescent-activated cell sorting for peptide-reactive CD4<sup>+</sup> and CD8<sup>+</sup> T cells. All events were gated on lymphocytes, single cells, and subsequently selected for CD4 positive or CD8 positive cells. Activated CD4<sup>+</sup> or CD8<sup>+</sup> T cells were sorted based on increased expression of CD137 compared to DMSO.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82050-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>T cell receptor (TCR) sequence and pp65 peptide identification of 4UGT8 clone.</title><p>(<bold>A</bold>) Figure showing TCR sequencing of three cross-reactive CD4<sup>+</sup> T cell clones. (<bold>B</bold>) Heatmap showing reactivity of 4UGT8 clone after co-culturing with HLA-matched EBV-lymphoblastoid cell lines (EBV-LCLs) and cytomegalovirus (CMV) pp65 peptide library which consisted of 12 horizontal (H1–H12) and 12 vertical sub pools (V1–V12). Reactivity was measured by IFN-γ ELISA of the supernatant, depicted as OD-value. Peptides that were present in the sub pools with highest reactivity are shown below the figure. (<bold>C</bold>) Bar graphs showing IFN-γ secretion after co-culturing 4UGT8 clone with single peptides. Peptide sequences are depicted next to the figure with amino acid overlap between the peptides in bold. Data points are technical duplicates. (<bold>D</bold>) Bar graphs showing ELISA measurement of secreted IFN-γ after co-culturing of 4UGT8 clone with HLA-matched EBV-LCLs, or HLA-mismatched EBV-LCLs transduced with HLA-DPB1*04:02 or DRB1*11:01. Stimulator cells were peptide-pulsed with membrane (M) peptide pool, pp65 peptide pool, or AGILARNLVPM (AGI) peptide. Data points are experimental duplicates. Black arrows indicate that values were above plateau value of the ELISA calibration curve.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82050-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>T cell receptor (TCR) sequence and peptide identification of 8UTT6 clone.</title><p>(<bold>A</bold>) Figure showing TCR sequencing result of UTT clones (N=23). (<bold>B</bold>) Heatmap showing reactivity of a representative clone, 8UTT6 clone, against sub pools of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike peptide library loaded on K562s transduced with HLA-B*35:01. Reactivity was measured by IFN-γ ELISA. Peptides that induced highest IFN-γ production were depicted under the figure with amino acid overlap between the peptides in black. (<bold>C</bold>) Figure showing NetMHC 4.0-predicted binding to HLA-B*35:01 of peptides that were recognized in the spike peptide library. The 10 peptides with highest binding to HLA-B*35:01 are shown, and strong binders are indicated by an arrow. (<bold>D</bold>) Heatmap demonstrating peptide recognition signature of 8UTT6 clone using the combinatorial peptide library (CPL) assay. 8UTT6 clone was co-cultured with peptide-loaded K562 cells transduced HLA-B*35:01. Secreted IFN-γ was measured by ELISA and corrected per row. Y-axis shows peptide position, and x-axis shows the fixed amino acid. (<bold>E</bold>) Figure showing the 10 peptides with highest CPL score, their binding affinity to HLA-B*35:01 and strong binders are indicated by an arrow, as predicted by netMHC 4.0.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82050-fig2-figsupp3-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Similarity at the C-terminal part of the peptides could drive T cell cross reactivity</title><p>To understand the molecular basis of T cell cross reactivity between dissimilar peptides FVS and IPS, we modeled the FVS structure based on the solved structure of the IPS peptide bound to HLA-B*35:01 (<xref ref-type="fig" rid="fig3">Figure 3</xref>; <xref ref-type="bibr" rid="bib46">Pellicci et al., 2014</xref>). The two peptides share two residues (P3-S and P7-H) and have two similar residues (P6-T/V and P9-F/Y) based on similar biochemical properties and size. Residue substitutions from the IPS to FVS peptide were possible without major steric clashes with the HLA or peptide residues. The lack of secondary anchor residue at position 5 in the FVS peptide (P5-N/G) might change the conformation of the central part of the peptide that could be similar to the one observed in the spike-derived peptide IPF (S<sub>896-904</sub>) in complex with HLA-B*35:01 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib45">Nguyen et al., 2021</xref>). The primary anchor in the FVS peptide is P2-V and P9-F, both within the favored residues at those positions for HLA-B35-restricted peptide (<xref ref-type="bibr" rid="bib20">Escobar et al., 2008</xref>). Overall, the FVS peptide might adopt a similar backbone conformation compared to the IPS peptide, which would place in both peptides a small hydrophobic residue at position 6 (P6-T/V), a histidine at position 7, and a residue with a large side-chain at position 8 (P8-W/H).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Model of the HLA-B*35:01-FVS structure.</title><p>(<bold>A</bold>) Crystal structure of the HLA-B*35:01-IPS complex with the HLA in white cartoon and the IPS peptide in clear orange cartoon and stick. (<bold>B</bold>) Model of the HLA-B*35:01-FVS complex with the HLA in white cartoon and the FVS peptide in blue cartoon and stick. The sphere represents the Cα atom of the FVS peptide P5-G residue.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82050-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Structural overlay of HLA-B*35:01-IPF structure with the model of the HLA-B*35:01-FVS.</title><p>(<bold>A</bold>) Top view of the HLA-B*35:01-IPF (peptide in chartreuse) and HLA-B*35:01-FVS (peptide in blue) aligned on the HLA cleft (white cartoon). (<bold>B</bold>) Side view of the same structural overlay as panel A, with the same color scheme. The sphere represents the Cα atom of the FVS peptide P5-G residue.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82050-fig3-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>IPS/FVS-specific cross-reactive CD8<sup>+</sup> T cells are detectable in multiple individuals</title><p>To investigate the prevalence and phenotype of IPS/FVS cross-reactive T cells, HLA-B*35:01<sup>+</sup> CMV<sup>+</sup> healthy donors were screened for IPS/FVS-specific T cells using tetramers consisting of HLA-B*35:01-FVS (B*35/FVS-tetramer) and HLA-B*35:01-IPS (B*35/IPS-tetramer; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Tetramer staining of PBMCs from donor UTT demonstrated that not all T cells that bound to B*35/IPS-tetramer were able to bind to the B*35/FVS-tetramer as well. However, all T cells that bound to B*35/FVS-tetramer were also binding to the B*35/IPS-tetramer (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). This observation indicates that IPS/FVS cross-reactivity is dictated by specific TCR sequences which were further supported by the lack of binding to B*35/FVS-tetramer by an IPS-specific T cell clone with a different TCR (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Screening of SARS-CoV-2-unexposed, CMV<sup>+</sup>, and HLA-B*35(:01) donors (N=37) showed that nearly all CMV<sup>+</sup> donors had IPS-specific T cells with frequencies above background level, and interestingly, three of the analyzed donors (UTT, UBV, and SFW) presented with clearly detectable IPS/FVS-specific T cells (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Furthermore, IPS/FVS-specific T cells displayed an effector memory phenotype (CCR7<sup>−</sup>CD45RA<sup>−</sup>), confirming a memory repertoire origin and, interestingly, a less differentiated phenotype compared to IPS-specific T cells (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). In summary, IPS/FVS cross reactivity is dependent on the TCR clonotype, and these cross-reactive T cells are detected in multiple donors.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Tetramer detection of IPS/FVS-specific CD8<sup>+</sup> T cells in CMV<sup>+</sup> and HLA-B*35:01<sup>+</sup> donors.</title><p>Flow cytometry measurement of PBMCs or T cell clones that are binding to B*35/IPS-tetramer (blue), B*35/FVS-tetramer (purple), or to neither (gray). (<bold>A</bold>) Flow cytometry dot plot showing percentages of tetramer-binding cells of total CD8<sup>+</sup> T cells in PBMCs from donor UTT. (<bold>B</bold>) Dot plot showing percentages of tetramer-binding of 8UTT6 clone and an IPS-specific clone with their international immunogenetics information system (IMGT) variable region of T cell receptor β-chain (TRBV) depicted. As a negative control (neg. ctrl.), a T cell clone recognizing a non-relevant peptide in HLA-B*35:01 was included. (<bold>C</bold>) Bar graph showing frequencies of tetramer-binding of total CD8<sup>+</sup> from PBMCs of healthy CMV<sup>+</sup> and HLA-B*35(:01)<sup>+</sup> donors. Error bars represent SD of experimental duplicates. Dotted line represents background level which was based on HLA-B*35:01<sup>−</sup> donors (neg.). (<bold>D</bold>) Dot plot showing expression of CCR7 and CD45RA by total CD8<sup>+</sup> T cells and tetramer-binding T cells in PBMCs from UTT, UBV, and SFW. Quadrants separate differentiation subsets into naïve (N), central memory (CM), effector memory (EM), and terminally differentiated effector memory (TEMRA).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82050-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Flow cytometry gating example for tetramer staining assays.</title><p>Representative example of flow cytometry gating strategy for tetramer positive CD8<sup>+</sup> T cells. All events were gated on lymphocytes, single cells, viable cells, CD8 positive, and subsequently separated for binding to tetramer consisting of HLA-B*35:01 with IPS peptide or FVS peptide.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82050-fig4-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-5"><title>IPS/FVS cross reactivity is underpinned by a public TCR</title><p>To investigate whether the IPS/FVS-specific CD8<sup>+</sup> T cells found in multiple donors expressed a similar TCR, B*35/FVS-tetramer-binding T cells were isolated and the TCR α and β chains sequenced (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Sequencing was performed for samples with clear detection of IPS/FVS-specific T cells (UTT, UBV, and SFW) and one donor with detectable, but below the limit of accurate detection of B*35/FVS-tetramer<sup>+</sup> T cells (JZX; <xref ref-type="fig" rid="fig4">Figure 4C</xref>). Interestingly, B*35/FVS-isolated T cells from all donors displayed amino acid identical dominant complementary-determining region 3 (CDR3) of the α-chain, CAGNQGGKLIF (CDR3α<sup>CAGNQG</sup>), and β-chain, CASSLALDEQFF (CDR3β<sup>CASSLA</sup>; <xref ref-type="fig" rid="fig5">Figure 5A</xref>). This observation thereby shows that IPS/FVS cross reactivity is caused by a public TCR. These identical CDR3s were not a result of sequencing artifact as nucleotide alignment revealed minor differences between samples (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). In addition to B*35/FVS-isolated T cells, T cells that bound B*35/IPS-tetramer were isolated and sequenced in parallel. Both CDR3α<sup>CAGNQG</sup> and CDR3β<sup>CASSLA</sup> were identified in all samples and shown to be among the most dominant TCRs. Remarkably, this was also observed in donor JZX which showed IPS/FVS-tetramer<sup>+</sup> T cells below background level, indicating that in more than 3 out of 37 donors, this public TCR is present. (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Taken together, IPS/FVS-specific T cells express an identical TCR, found in multiple donors, indicating that public TCRs can exhibit cross-reactive properties.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>T cell receptor (TCR) sequencing of IPS/FVS-specific T cells.</title><p>PBMCs from healthy CMV<sup>+</sup> and HLA-B*35:01<sup>+</sup> donors were sorted on B*35/IPS- or B*35/FVS-tetramer binding and directly sequenced for their TCR alpha and beta chain. Unique CDR3 sequences are depicted in two-sided bar graphs in which the left side shows abundance of CDR3 sequences from the TCR α-chain (CDR3α), and the right side shows abundance of CDR3 sequences from the TCR β-chain (CDR3β). Bar graphs are purple if the CDR3α has the CAGNQGGKLIF sequence, or the CDR3β has the CASSLALDEQFF sequence; all other found sequences are depicted in blue. CDR3s with less than 1% abundance were excluded from the analysis. (<bold>A</bold>) Two-sided bar graphs showing abundances of unique CDR3 sequences of samples sorted on binding to B*35/FVS-tetramer. (<bold>B</bold>) Two-sided bar graphs showing abundances of unique CDR3 sequences of samples sorted on binding to B*35/IPS-tetramer.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>T cell receptor sequences of IPS/B*35 and FVS/B*35-specific CD8+ T cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-82050-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82050-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Flow activated cell sorting gating example.</title><p>Representative example of fluorescent-activated cell sorting for tetramer positive CD8<sup>+</sup> T cells. All events were gated on lymphocytes, single cells, CD4<sup>−</sup>, and subsequently on CD8<sup>+</sup>tetramer<sup>+</sup>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82050-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>T cell receptor (TCR) sequencing of B*35/FVS-sorted samples.</title><p>Nucleotide alignment of the CDR3 α and β sequence of PBMCs sorted on B*35/FVS-tetramer binding. Segment numbering is depicted according to the international immunogenetics information system (IMGT) nomenclature. (<bold>A</bold>) Nucleotide alignment of the CDR3α sequences. (<bold>B</bold>) Nucleotide alignment of the CDR3β sequences.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82050-fig5-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>IPS/FVS cross-reactive CD8<sup>+</sup> T cells are able to recognize SARS-CoV-2-infected cells but do not show an activated phenotype during acute disease</title><p>To investigate whether IPS/FVS-specific CD8<sup>+</sup> T cells can play a role during SARS-CoV-2 infection, the function of IPS/FVS-specific T cells in an in vitro model and the activation state of these T cells during acute SARS-CoV-2 infection in severe COVID-19 patients was assessed. Firstly, the reactivity of IPS/FVS-specific T cells against K562 transduced with the spike gene was measured which showed that the T cells were able to recognize endogenously processed and presented peptide (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). To investigate whether the IPS/FVS-specific T cells can recognize SARS-CoV-2-infected cells and thereby limit viral spread, Calu-3 airway epithelial cells were infected with live SARS-CoV-2 virus (wildtype) and incubated for 6 hr before co-culturing with CD8<sup>+</sup> T cells. SARS-CoV-2 spike-specific CD8<sup>+</sup> T cells from a SARS-CoV-2 vaccinated donor were able to reduce intracellular SARS-CoV-2 RNA copies at both 0.05 and 0.5 multiplicity of infection (MOI) 24 hr post infection (<xref ref-type="fig" rid="fig6">Figure 6B–C</xref>). Interestingly, IPS/FVS-specific CD8<sup>+</sup> T cells were able to reduce SARS-CoV-2 intracellular RNA copies in Calu-3 cells infected with 0.05 MOI (MOI <xref ref-type="fig" rid="fig6">Figure 6B</xref>). Incubating with 10-fold more virus (0.5 MOI) resulted in no difference in RNA copies compared to the no T cell control (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). To further investigate the function of IPS/FVS-specific CD8<sup>+</sup> T cells ex vivo, the activation state of these T cells was evaluated during severe COVID-19 disease in two CMV<sup>+</sup> HLA-B*35:01<sup>+</sup> patients. The activation state was measured by expression of activation markers CD38 and HLA-DR as these markers are highly expressed on SARS-CoV-2-specific CD8<sup>+</sup> T cells during severe COVID-19 (<xref ref-type="fig" rid="fig6">Figure 6D</xref>; <xref ref-type="bibr" rid="bib58">Sekine et al., 2020</xref>). Interestingly, IPS/FVS-cross-reactive T cells were detected in two out of two CMV<sup>+</sup> HLA-B*35:01<sup>+</sup> patients suffering from severe COVID-19, whereas the cross-reactive T cells were detected in 3 out of 37 healthy CMV<sup>+</sup> HLA-B*35:01<sup>+</sup> donors (<xref ref-type="fig" rid="fig4">Figures 4C</xref> and <xref ref-type="fig" rid="fig6">6E</xref>). The expression of CD38 and HLA-DR was lower compared to the SARS-CoV-2-specific CD8<sup>+</sup> T cells and not considerably increased compared to IPS-specific T cells that were not cross-reactive with FVS (<xref ref-type="fig" rid="fig6">Figure 6D–E</xref>). These results indicate that IPS/FVS-specific CD8<sup>+</sup> T cells recognize SARS-CoV-2-infected cells and are able to limit SARS-CoV-2 replication at low virus titers. However, IPS/FVS-specific T cells did not show an activated phenotype during acute severe SARS-CoV-2 infection.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Ex vivo and in vitro evaluation of IPS/FVS-specific T cells.</title><p>(<bold>A</bold>) IFN-γ release of IPS/FVS-specific CD8<sup>+</sup> T cells after co-incubation with K562 that were untransduced (x), loaded with spike peptide pool (S pep), or transduced with nucleotide 1–2082 (S1 gene) or nucleotide 2052–3,822 (S2 gene) of the spike gene. (<bold>B–C</bold>) Calu-3 cells were transduced to express HLA-B*35:01 and infected with the wildtype severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. 6 hr post infection (hpi), IPS/FVS-specific CD8<sup>+</sup> T cells were added in a 10:1 effector to target ratio. SARS-CoV-2 spike-specific T cells, isolated from coronavirus disease 2019 (COVID-19) vaccinated individuals, that recognize VASQSIIAY presented in HLA-B*35:01 or YLQPRTFLL presented in HLA-A*02:01 functioned as a positive control (pos.) or negative control (neg.), respectively. Cells were harvested 24 hpi to measure intracellular viral RNA. Bar graphs show the means of percentage reduction in SARS-CoV-2 intracellular RNA copies compared to the no T cell condition (no T) as measured by reverse transcription quantitative PCR (RT-qPCR), at 24 hpi using a multiplicity of infection (MOI) of 0.05 or 0.5. One-way ANOVA was applied to test statistical differences between conditions and only comparisons with p&lt;0.05 are shown. (<bold>D–E</bold>) Flow cytometry analysis of CD38 and HLA-DR expression on CD8<sup>+</sup> T cells in PBMCs from severe COVID-19 patients who were CD137<sup>+</sup>IFN-γ<sup>+</sup> after SARS-CoV-2 nucleocapsid peptide stimulation (red), only bound to B*35/IPS-tetramer (blue) or bound to both B*35/IPS- and B*35/FVS-tetramer (purple). All other CD8<sup>+</sup> T cells are gray. Two patients were HLA-B*35:01<sup>+</sup>CMV<sup>+</sup> (KDH and CHZ), and as a control, one patient was HLA-B*35:01<sup>+</sup>CMV<sup>−</sup> (CLS). Detection of B*35/IPS- and B*35/FVS-specific T cells and expression of the activation markers were measured and compared within the same sample.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82050-fig6-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>SARS-CoV-2-specific T cells in pre-pandemic cryo-preserved samples have been reported in several studies. The majority of these studies describe T cell immunity against other HCoVs as the main source of these T cells (<xref ref-type="bibr" rid="bib5">Bacher et al., 2020</xref>; <xref ref-type="bibr" rid="bib11">Braun et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Johansson et al., 2021</xref>; <xref ref-type="bibr" rid="bib33">Kundu et al., 2022</xref>; <xref ref-type="bibr" rid="bib34">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Loyal et al., 2021</xref>; <xref ref-type="bibr" rid="bib41">Mateus et al., 2020</xref>). However, some studies have postulated that pre-pandemic SARS-CoV-2-specific T cells could be derived from other sources (<xref ref-type="bibr" rid="bib34">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Peng et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Stervbo et al., 2020</xref>; <xref ref-type="bibr" rid="bib68">Tan et al., 2021b</xref>). Our findings demonstrate that CMV pp65-specific CD4<sup>+</sup> T cells cross react with the membrane protein from SARS-CoV-2, and CMV pp65-specific CD8<sup>+</sup> T cells are able to cross react with SARS-CoV-2 spike protein. The cross-reactive CD8<sup>+</sup> T cells recognized known CMV epitope IPSINVHHY in HLA-B*35:01 and cross reacted with the SARS-CoV-2 epitope FVSNGTHWF in HLA-B*35:01. These IPS/FVS-specific CD8<sup>+</sup> T cells were detected in multiple donors all expressing an identical TCR, indicating that cross-reactivity with SARS-CoV-2 can be caused by a CMV-specific public TCR. Functional and phenotypic assessment of the IPS/FVS-specific CD8<sup>+</sup> T cells indicated their capacity to reduce low concentrations of SARS-CoV-2 in vitro, but these cross-reactive T cells detected in two severe COVID-19 patients were not activated based on phenotypic characterization.</p><p>To our knowledge this is the first study to identify CMV-specific T cells that are cross reactive with SARS-CoV-2. The cross-reactive CD4<sup>+</sup> T cells recognized CMV pp65 epitope AGILARNLVPM in HLA-DRB3*02:02 and were able to cross react with an as of yet unidentified, SARS-CoV-2 membrane epitope in HLA-DRB3*02:02 (<xref ref-type="bibr" rid="bib71">Weber et al., 2022</xref>). Previous studies have reported the presence of membrane-specific CD4<sup>+</sup> T cell responses in SARS-CoV-2-unexposed donors utilizing the same commercially available membrane peptide pool, yet these studies did not aim to identify the peptide-HLA restriction (<xref ref-type="bibr" rid="bib5">Bacher et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Sekine et al., 2020</xref>). AGI-specific CD4<sup>+</sup> T cells have been described to be cross reactive toward SARS-CoV-2 spike which is in contrast to our finding (<xref ref-type="bibr" rid="bib71">Weber et al., 2022</xref>). The cross-reactive CD8<sup>+</sup> T cells recognize the CMV epitope IPSINVHHY and SARS-CoV-2 epitope FVSNGTHWF presented in HLA-B*35:01. IPS/FVS-specific T cells were possibly detected previously but never further investigated or characterized (<xref ref-type="bibr" rid="bib60">Shomuradova et al., 2020</xref>; <xref ref-type="bibr" rid="bib69">Tarke et al., 2021</xref>). Both cross-reactive CD4<sup>+</sup> and CD8<sup>+</sup> T cells displayed a higher avidity for the CMV epitope compared to the epitope derived from SARS-CoV-2. In contrast, other studies have reported an equal or even higher avidity for the SARS-CoV-2 epitope compared to the epitopes derived from the HCoV for which the T cells were hypothesized to be primed against (<xref ref-type="bibr" rid="bib11">Braun et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Johansson et al., 2021</xref>; <xref ref-type="bibr" rid="bib37">Lineburg et al., 2021</xref>; <xref ref-type="bibr" rid="bib41">Mateus et al., 2020</xref>). This appears to be contradictive since it has been shown that repeated exposure results in the selection of high avidity T cell clonotypes which are able to clear viral infection and protect against reinfection (<xref ref-type="bibr" rid="bib1">Abdel-Hakeem et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Hombrink et al., 2013</xref>; <xref ref-type="bibr" rid="bib50">Price et al., 2005</xref>; <xref ref-type="bibr" rid="bib57">Schober et al., 2018</xref>). Cross-reactive T cells would therefore most likely display a higher avidity for the source pathogen compared to the avidity for SARS-CoV-2, as reported in this study. This discrepancy could be caused by the fact that previous studies focused on other HCoVs since they share high sequence homology with SARS-CoV-2, thereby potentially missing the true source of these particular T cells (<xref ref-type="bibr" rid="bib5">Bacher et al., 2020</xref>; <xref ref-type="bibr" rid="bib11">Braun et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Johansson et al., 2021</xref>; <xref ref-type="bibr" rid="bib33">Kundu et al., 2022</xref>; <xref ref-type="bibr" rid="bib34">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Loyal et al., 2021</xref>; <xref ref-type="bibr" rid="bib41">Mateus et al., 2020</xref>). Alternatively, samples frozen down during the pandemic were considered unexposed if the donors displayed neither SARS-CoV-2-specific antibodies nor a history of COVID-19-like symptoms (<xref ref-type="bibr" rid="bib5">Bacher et al., 2020</xref>; <xref ref-type="bibr" rid="bib11">Braun et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Lineburg et al., 2021</xref>). However, SARS-CoV-2 infection does not necessarily lead to symptoms or a detectable antibody response (<xref ref-type="bibr" rid="bib21">Gao et al., 2021</xref>; <xref ref-type="bibr" rid="bib61">Steiner et al., 2021</xref>). The described reduced avidity for HCoV therefore could imply that these cross-reactive T cells were derived from the SARS-CoV-2-induced repertoire. Taken together, whereas cross-reactive T cells recognizing SARS-CoV-2 have been primarily described to be derived from other HCoVs, the contribution of these other HCoVs as initial primers of the T cell response may have been over-estimated due to experimental design. Further studies are required to identify other potential sources of cross reactivity with low sequence homology yet high prevalences such as CMV, EBV, influenza, or non-viral pathogens.</p><p>The identified cross-reactive CD8<sup>+</sup> T cells appeared to recognize CMV peptide IPSINVHHY and a dissimilar peptide FVSNGTHWF derived from SARS-CoV-2. Ex vivo detected heterologous CD8<sup>+</sup> T cell immunity against two pathogens caused by dissimilar epitopes presented in the same HLA is rarely reported (<xref ref-type="bibr" rid="bib16">Clute et al., 2005</xref>; <xref ref-type="bibr" rid="bib18">Cornberg et al., 2010</xref>). Nevertheless, ample studies have investigated the underlying mechanisms of such T cell-mediated cross reactivity. Heterologous immunity can be caused by the expression of a dual TCR which means that two TCR α- or β-chains are expressed simultaneously, resulting in two distinctive TCRs within one T cell (<xref ref-type="bibr" rid="bib19">Cusick et al., 2012</xref>). However, here, we identified a single TCR in cross-reactive T cells excluding this hypothesis. Recognition of two distinct epitopes by a single TCR can be explained by shape similarity once the peptides are bound to the HLA molecule, and this shape similarity, or molecular mimicry can underpin T cell cross reactivity (<xref ref-type="bibr" rid="bib40">Macdonald et al., 2009</xref>). Possible other underlying mechanisms are reduced footprint of the TCR with peptide (<xref ref-type="bibr" rid="bib9">Birnbaum et al., 2014</xref>; <xref ref-type="bibr" rid="bib17">Cole et al., 2016</xref>), an altered TCR-docking angle (<xref ref-type="bibr" rid="bib2">Adams et al., 2011</xref>), or plasticity of the peptide-MHC complex (<xref ref-type="bibr" rid="bib2">Adams et al., 2011</xref>; <xref ref-type="bibr" rid="bib53">Riley et al., 2018</xref>) or TCR (<xref ref-type="bibr" rid="bib49">Piepenbrink et al., 2013</xref>). Here, similarity between the IPS and FVS peptides in backbone conformation and the C-terminal part might underpin the T cell cross reactivity observed, as the majority of TCR docks preferentially toward the C-terminal of the peptide (<xref ref-type="bibr" rid="bib65">Szeto et al., 2020</xref>). Solving the crystal structure of the IPS/FVS-TCR binding to HLA-B*35:01-FVS and -IPS would be necessary to provide insight in the binding properties of the public TCR.</p><p>IPS/FVS-specific CD8<sup>+</sup> T cells were able to reduce SARS-CoV-2 spread in vitro when exposed to a low virus concentration, which is supported by our finding that two out of two tested severe COVID-19 patients had clearly detectable IPS/FVS-specific CD8<sup>+</sup> T cells, while the prevalence in healthy donors was 3 out of 37. The presence of these cross-reactive memory T cells in circulation may be an advantage during initial SARS-CoV-2 infection as rapid T cell responses were associated with less severe COVID-19 (<xref ref-type="bibr" rid="bib39">Loyal et al., 2021</xref>; <xref ref-type="bibr" rid="bib59">Sette and Crotty, 2021</xref>; <xref ref-type="bibr" rid="bib67">Tan et al., 2021a</xref>). However, the cross-reactive CD8<sup>+</sup> T cells were less efficient compared to SARS-CoV-2-specific, vaccination-primed T cells in limiting viral spread in vitro which can be explained by the reduced avidity of the cross-reactive T cells for the spike protein compared to CMV. This study also demonstrated that IPS/FVS-specific CD8<sup>+</sup> T cells did not display the same degree of activation as observed for the SARS-CoV-2-specific T cells during severe COVID-19. Additionally, despite the presence of the cross-reactive CD8<sup>+</sup> T cells, these individuals developed severe disease. These observations together indicate that IPS/FVS-specific CD8<sup>+</sup> T cells might be able to reduce SARS-CoV-2 spread at initial infection but likely do not play a significant role in the pathogenesis of severe COVID-19. One limitation is that our study focused on circulating T cells, and we cannot exclude the possibility that cross-reactive CD8<sup>+</sup> T cells present in lung tissue did display an activated phenotype. Another limitation of this study is the small severe COVID-19 cohort that was investigated, and literature describing the role of cross-reactive T cells is scarce (<xref ref-type="bibr" rid="bib5">Bacher et al., 2020</xref>; <xref ref-type="bibr" rid="bib33">Kundu et al., 2022</xref>). In summary, additional studies using larger cohorts are required to fully elucidate the potential role of cross-reactive CD8<sup>+</sup> T cells in disease.</p><p>In conclusion, pre-pandemic SARS-CoV-2-specific T cells can derive from non-homologous pathogens such as CMV. This expands the potential origin of these pre-pandemic SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell beyond other HCoVs. The cross-reactive CD8<sup>+</sup> T cells were reactive toward dissimilar epitopes, and this cross reactivity was caused by a public TCR, which has been rarely observed so far. Our data points toward a role of the cross-reactive T cells in reducing SARS-CoV-2 viral load in the early stages of infection, prior to priming of SARS-CoV-2 specific T cells. Altogether, these results aid in further understanding heterologous T cell immunity beyond common cold coronaviruses and facilitate the investigation into the potential role of cross-reactive T cells in COVID-19.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike (S), 15-mers, 11aa overlapping peptide pool</td><td align="left" valign="bottom">Miltenyi</td><td align="char" char="hyphen" valign="bottom">130-126-701</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">SARS-CoV-2 Spike (S1), 15-mers, 11aa overlapping peptide pool</td><td align="left" valign="bottom">Miltenyi</td><td align="char" char="hyphen" valign="bottom">130-127-041</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">SARS-CoV-2 Spike (S+), 15-mers, 11aa overlapping peptide pool</td><td align="left" valign="bottom">Miltenyi</td><td align="char" char="hyphen" valign="bottom">130-127-312</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">SARS-CoV-2 Membrane (M), 15-mers, 11aa overlapping peptide pool</td><td align="left" valign="bottom">Miltenyi</td><td align="char" char="hyphen" valign="bottom">130-126-703</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">SARS-CoV-2 Nucleocapsid (N), 15-mers, 11aa overlapping peptide pool</td><td align="left" valign="bottom">Miltenyi</td><td align="char" char="hyphen" valign="bottom">130-126-699</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Cytomegalovirus (CMV) pp65, 15-mers, 11aa overlapping peptide pool</td><td align="left" valign="bottom">JPT</td><td align="left" valign="bottom">Custom-made</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">CMV pp65 peptide library, 15-mers, 11aa overlapping</td><td align="left" valign="bottom">JPT</td><td align="left" valign="bottom">Custom-made</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">SARS-CoV-2 Spike peptide library, 15-mers, 11aa overlapping</td><td align="left" valign="bottom">SB Peptides</td><td align="left" valign="bottom">SB043</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">CMV, VFTWPPWQAGILARN</td><td align="left" valign="bottom">LUMC</td><td align="left" valign="bottom">Custom-made</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">CMV, PPWQAGILARNLVPM</td><td align="left" valign="bottom">LUMC</td><td align="left" valign="bottom">Custom-made</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">CMV, AGILARNLVPMVATV</td><td align="left" valign="bottom">LUMC</td><td align="left" valign="bottom">Custom-made</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">CMV, ARNLVPMVATVQGQN</td><td align="left" valign="bottom">LUMC</td><td align="left" valign="bottom">Custom-made</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">CMV, VPMVATVQGQNLKYQ</td><td align="left" valign="bottom">LUMC</td><td align="left" valign="bottom">Custom-made</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">CMV, AQGDDDVWTSGSDSD</td><td align="left" valign="bottom">LUMC</td><td align="left" valign="bottom">Custom-made</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">CMV, SSATACTSGVMTRGR</td><td align="left" valign="bottom">LUMC</td><td align="left" valign="bottom">Custom-made</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">CMV, PKRRRHRQDALPGPC</td><td align="left" valign="bottom">LUMC</td><td align="left" valign="bottom">Custom-made</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">SARS-CoV-2, FVSNGTHWF</td><td align="left" valign="bottom">LUMC</td><td align="left" valign="bottom">Custom-made</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">CMV, IPSINVHHY</td><td align="left" valign="bottom">LUMC</td><td align="left" valign="bottom">Custom-made</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-human CCR7 (BV711)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat.#563712 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2738386">AB_2738386</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human CD137 (APC)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat.#550890 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_398477">AB_398477</ext-link></td><td align="left" valign="bottom">FC (1:75)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human CD14 (FITC)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat.#555397 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_395798">AB_395798</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human CD154 (Pacific Blue)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat.#310820 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_830699">AB_830699</ext-link></td><td align="left" valign="bottom">FC (1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human CD19 (FITC)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat.#555412 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_395812">AB_395812</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human CD4 (PE-Cy7)</td><td align="left" valign="bottom">Beckham Coulter</td><td align="left" valign="bottom">Cat.#737660 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2922769">AB_2922769</ext-link></td><td align="left" valign="bottom">FC (1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human CD4 (FITC)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat.#555346 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_395751">AB_395751</ext-link></td><td align="left" valign="bottom">FC (1:30)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human CD4 (BV510)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat.#562970 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2744424">AB_2744424</ext-link></td><td align="left" valign="bottom">FC (1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human CD45RA (PE-Texas-Red)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat.#MHCD45RA17 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10372222">AB_10372222</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human CD8 (APC-H7)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat.#560179 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1645481">AB_1645481</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human CD8 (PE-Cy7)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat.#557746 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_396852">AB_396852</ext-link></td><td align="left" valign="bottom">FC (1:320)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human CD8 (Pacific Blue)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat.#558207 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_397058">AB_397058</ext-link></td><td align="left" valign="bottom">FC (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human IFN-γ (Alexa-Fluor 700)</td><td align="left" valign="bottom">Sony</td><td align="left" valign="bottom">Cat.#3112600 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2922770">AB_2922770</ext-link></td><td align="left" valign="bottom">FC (1:120)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human IFN-γ (BV711)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat.#564039 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2738557">AB_2738557</ext-link></td><td align="left" valign="bottom">FC (1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human HLA-DR (Alexa-Fluor 700)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat.#560743 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1727526">AB_1727526</ext-link></td><td align="left" valign="bottom">FC (1:150)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-human CD38 (BV605)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat.#740401 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2740131">AB_2740131</ext-link></td><td align="left" valign="bottom">FC (1:120)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse CD19 (Mouse)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat.#557399 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_396682">AB_396682</ext-link></td><td align="left" valign="bottom">FC (1:250)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Zombie-Red</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat.#423109</td><td align="left" valign="bottom">FC (1:1000)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Zombie-Aqua</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat.#423101</td><td align="left" valign="bottom">FC (1:1000)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Brilliant Violet Staining Buffer Plus</td><td align="left" valign="bottom">Beckham Coulter</td><td align="left" valign="bottom">Cat.#566385</td><td align="left" valign="bottom">FC (1:10)</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">K-562</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CCL-342</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Calu-3</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-55</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">PBMCs from 67 healthy donors</td><td align="left" valign="bottom">LUMC Biobank</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cryo-preserved before May 2019</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">PBMCs from critical COVID-19 patient (KDH)</td><td align="left" valign="bottom">LUMC BEAT-COVID consortium</td><td align="left" valign="bottom">Clinical trial #: NL8589</td><td align="left" valign="bottom">Male, 61 years, 31 days ICU</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">PBMCs from critical COVID-19 patient (CHZ)</td><td align="left" valign="bottom">LUMC BEAT-COVID consortium</td><td align="left" valign="bottom">Clinical trial #: NL8589</td><td align="left" valign="bottom">Male, 76 years, 40 days ICU</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">PBMCs from critical COVID-19 patient (CLS)</td><td align="left" valign="bottom">LUMC BEAT-COVID consortium</td><td align="left" valign="bottom">Clinical trial #: NL8589</td><td align="left" valign="bottom">Male, 71 years, 107 days ICU</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Study samples and cell lines</title><p>Bio-banked PBMCs were cryopreserved after informed consent from the respective donors in accordance with the declaration of Helsinki. The samples from COVID-19 patients were part of a trial (NL8589) registered in the Dutch Trial Registry and approved by Medical Ethical Committee Leiden-Den Haag-Delft (NL73740.058.20). All three patients suffered from critical COVID-19 as categorized according to WHO guidelines (WHO ref#: WHO/2019-nCoV/clinical/2020.4; see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> for patient details). Bio-banked PBMCs from CMV-seropositive (N=28) and CMV-seronegative (N=39) donors that were frozen down before May 2019 were randomly selected to assure that the samples are SARS-CoV-2 naïve and represent the European population (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Prior to cryopreservation, PBMCs were isolated from fresh whole blood using Ficoll-Isopaque. PBMCs were thawed in culture medium consisting of Iscove Modified Dulbecco Medium (IMDM; Lonza, Basel, Switzerland) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma-Aldrich, Saint Louis, MO, USA), 2.7 mM L-glutamine (Lonza), 100 U/mL penicillin (Lonza), and 100 µg/mL streptomycin (Lonza; 1% p/s), and subsequently treated with 1.33 mg/mL DNAse to minimize cell clumping. K562 cells (<italic>CCL-243;</italic> American Type Culture Collection [ATCC]) and Calu-3 lung carcinoma cells (<italic>HTB-55;</italic> ATCC) were regularly checked for the presence of mycoplasma. K562s were regularly checked to ensure (lack of) HLA expression, and calu-3 cells were authenticated by STR sequencing.</p></sec><sec id="s4-2"><title>Intracellular cytokine staining assay</title><p>Thawed PBMCs were stimulated in culture medium supplemented with 1 µg/mL SARS-CoV-2 peptides pools covering the entire spike (Miltenyi, Keulen, Germany), membrane (Miltenyi), or nucleocapsid (Miltenyi) proteins for 1 hr at 37°C + 5% CO<sub>2</sub>. The peptides of the spike gene were by the manufacturer divided over an ‘S,’ ‘S1,’ and ‘S+’ pool, wherein ‘S’ covers the most immunogenic parts of the gene, ‘S1’ mostly covers S1 domain, and ‘S+’ mostly covers S2 domain. An additional peptide pool containing 11 amino acid overlapping 15-mer peptides covering the pp65 antigen from CMV (JPT Peptide Technologies) was included (see <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref> for peptide details). After 1 hr stimulation, 5 µg/mL Brefeldin A (Sigma-Aldrich) was added, and the samples were incubated for an additional 15 hr at 37°C + 5% CO<sub>2</sub>. The samples were subsequently stained with the viability dye Zombie-Red (Biolegend, San Diego, CA, USA) for 25 min at room temperature (RT) after which the cells were washed in PBS containing 0.8 mg/mL albumin (fluorescent activated cell sorting [FACS] buffer) and stained with antibodies against CD4 and CD8 in FACS buffer for 30 min at 4°C. Cells were washed in PBS and fixed in 1% paraformaldehyde for 8 min at RT followed by a wash and a permeabilization step for 30 min at 4°C in FACS buffer supplemented with 1% p/s and 0.1% saponin (permeabilization buffer). After permeabilization, the cells were stained using an antibody cocktail directed against CD14, CD19, CD137, CD154, and IFN-γ in permeabilization buffer (see <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref> for antibody details) for 30 min at 4°C. After staining, the samples were washed, resuspended in permeabilization buffer, and measured on a 3-laser aurora (Cytek Biosciences, Fremont, CA, USA).</p></sec><sec id="s4-3"><title>Isolation of SARS-CoV-2-specific T cells</title><p>Thawed PBMCs were stimulated for 16 hr at 37°C + 5% CO<sub>2</sub> using 1 µg/mL of spike (Miltenyi) or membrane (Miltenyi) peptide pool in culture medium (see <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref> for peptide details). After stimulation, the cells were washed and stained with antibodies directed against CD4, CD8, and CD137 in phenol-red free IMDM (Gibco, Waltham, MA, USA) containing 2% FBS (Sigma-Aldrich), 1% p/s (Lonza; sort medium; see <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref> for antibody details) for 30 min at 4°C. The cells were subsequently washed and resuspended in sort medium. CD4<sup>+</sup> or CD8<sup>+</sup> and CD137<sup>+</sup> cells were single-cell sorted using an Aria III cell sorter (BD Biosciences, Franklin Lakes, NJ, USA) into a 96-well round-bottom plate containing 1×10<sup>5</sup> 35-Gy-irradiated PBMCs, 50-Gy-irradiated EBV-LCL-JYs, and 0.8 µg/mL phytohemagglutinin (PHA) (Thermo Fisher, Waltham, MA, USA) in 100 µL T cell medium (TCM) consisting of IMDM (Lonza) supplemented with 2.7 mM L-glutamine (Lonza), 100 U/mL penicillin (Lonza), 100 µg/mL streptomycin (Lonza), 5% FBS (Sigma-Aldrich), 5% human serum (Sanquin, Amsterdam, The Netherlands), and 100 IU/mL recombinant human IL-2 (Novartis, Basel, Switzerland). Sorted T cells were clonally expanded to generate T cell clones. T cell clones were restimulated between day 14 and day 20 post stimulation using PHA, PBMCs, and EBV-LCL-JYs as described above and used for assays between day 7 and day 20 post stimulation.</p></sec><sec id="s4-4"><title>Co-culture assays</title><p>To test peptide and HLA restriction, T cell clones were washed and co-cultured with stimulator cells in a 1:6 effector to stimulator ratio. Stimulator cells consisted of either autologous or HLA-matched EBV-LCLs or retrovirally transduced K562s. K562 were transduced with a pZLRS or MP71 vector containing a HLA gene of interested linked to a marker gene, and transduction was performed as previously described (<xref ref-type="bibr" rid="bib26">Jahn et al., 2015</xref>). Cells were enriched for marker gene expression using magnetic activated cell sorting (MACS; Miltenyi) or FACS on an Aria III cell sorter (BD Biosciences). Stimulator cells were loaded with peptides through pre-incubation for 30 min at 37°C with 0.01–1 µM peptide (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref> for peptide details). To identify the pp65 epitope of the CD4<sup>+</sup> T cell clones, a co-culture assay was performed using a pp65 peptide library. The pp65 library consisted of 15-mere peptides with 11 amino acid overlap, spanning the whole pp65 gene. The peptides are divided into matrix pools with horizontal and vertical sub pools so that each pool has an unique peptide combination, and each peptide is in one horizontal and one vertical sub pool. To identify the HLA-restriction of the CD4<sup>+</sup> T cell clones, the peptides were not washed away during the co-culture incubation period, and HLA class II was knocked out in the T cell clones as previously described (<xref ref-type="bibr" rid="bib43">Morton et al., 2020</xref>). However, the protocol was adapted to knock-out Class II Major histocompatibility complex transactivator (CIITA) by designing two reverse guide RNAs: 5’-<named-content content-type="sequence">AGTCGCTCACTGGTCCCACTAGG</named-content>-3’ and 5’-<named-content content-type="sequence">CCGTGGACAGTGAATCCACTGGG</named-content>-3’ (Integrated DNA technologies Inc, Coralville, IA, USA). Co-culture assays were incubated overnight, and secreted IFN-γ was measured as an indicator of T cell activity by ELISA (Diaclone, Besançon, France) as described by the manufacturer.</p><p>To identify the peptide recognition signature of the CD8 T cell clones, a co-culture assay was performed using a nonamer CPL (<xref ref-type="bibr" rid="bib8">Bijen et al., 2018</xref>). The 9-mer CPL scan contains 180 peptide pools with each pool consisting of a mixture of peptides with one naturally-occurring amino acid fixed at one position (<xref ref-type="bibr" rid="bib73">Wooldridge et al., 2010</xref>). Co-culture assay was performed as described above with small changes; 2×10<sup>4</sup> K562 transduced with HLA-B*35:01 was pre-incubated with 100 µM CPL peptides for 1 hr at 37°C before 5×10<sup>3</sup> T cell clones were added. After overnight incubation, secreted IFN-γ was measured by an IFN-γ-ELISA (Diaclone), and results were analyzed using WSBC PI CPL for viruses (<xref ref-type="bibr" rid="bib66">Szomolay et al., 2016</xref>; <xref ref-type="bibr" rid="bib74">Wooldridge, 2013</xref>). Identified peptides following peptide libraries or CPL were analyzed for predicted binding to HLA-B*35:01 using netMHC 4.0 (<xref ref-type="bibr" rid="bib4">Andreatta and Nielsen, 2016</xref>). Alternatively, peptide recognition by T cell clones was measured using intracellular cytokine staining (ICS) assay as described above.</p></sec><sec id="s4-5"><title>Peptide-HLA modeling</title><p>The binding of FVS in HLA-B*35:01 was modeled based on the solved crystal structure of the HLA-B*35:01-IPS (<xref ref-type="bibr" rid="bib46">Pellicci et al., 2014</xref>). Each residue of the IPS peptide was mutated to their corresponding residues in the FVS peptide using the mutagenesis wizard in <xref ref-type="bibr" rid="bib51">PyMOL, 2015</xref>. The residues were mutated into the most favorable rotamer to avoid steric clashes. No major steric clashes with the peptide or HLA were observed.</p></sec><sec id="s4-6"><title>Tetramer staining</title><p>1–2×10<sup>6</sup> PBMCs or 5×10<sup>4</sup> T cell clones were incubated with in-house generated, PE- or APC-conjugated tetramers for 30 min at RT (<xref ref-type="bibr" rid="bib25">Hombrink et al., 2013</xref>). After tetramer incubation, the cells were washed and incubated with an antibody mix targeting CD4, CD8, CD45RA, CCR7, CD38, and/or HLA-DR. After incubation, cells were washed and resuspended in FACS buffer and immediately measured on a 3-laser Aurora (Cytek Biosciences).</p></sec><sec id="s4-7"><title>TCR sequencing</title><p>PBMCs were thawed and 10–50×10<sup>6</sup> cells directly stained with PE-conjugated HLA-B*35:01-FVS or HLA-B*35:01-IPS tetramers. Tetramers were labeled to beads using anti-PE MicroBeads (Miltenyi) and enriched through magnetic-activated cell sorting (Miltenyi). The tetramer-enriched cells were washed and incubated with an antibody cocktail targeting CD4 and CD8 (see <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref> for antibody details) in sort medium. Stained samples were washed in sort medium and bulk-sorted on an Aria III cell sorter (BD Biosciences; see <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> for a gating example). RNA isolation and TCR sequencing were performed as previously described (<xref ref-type="bibr" rid="bib54">Roukens et al., 2022</xref>). In short, cells were directly collected in lysis buffer for RNA isolation using the ReliaPrep RNA cell Miniprep system (Promega, Madison, WI, USA). The total RNA yield of each sample was converted to cDNA using a template-switch oligo primer (Eurogentec, Seraing, Belgium), RNAsin (Promega), and SMARTScribe reverse transcriptase (Takara Bio, Kusatsu, Japan; <xref ref-type="bibr" rid="bib32">Koning et al., 2017</xref>). cDNA was pre-amplified via an IS region in the Oligo dT primer prior to barcoding on samples containing cDNA from 500 or fewer cells (<xref ref-type="bibr" rid="bib48">Picelli et al., 2013</xref>). Barcoded TCR PCR product was generated in two rounds of PCR: in the first PCR reaction, <italic>TRA</italic> and <italic>TRB</italic> product was generated in separate PCR reactions using Phusion Flash (Thermo Fisher Scientific), Smartseq2modified PCR primer (Eurogentec), and TRAC or TRBC1/2-specific primers (Eurogentec; see <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref> for primer list). The PCR product was then purified using the Wizard SV 96 PCR Clean-Up System (Promega) and barcoded in a second PCR using two-sided six-nucleotide barcoded primers to discriminate between TCRs of different T cell populations. PCR products of different T cell populations were pooled, after which TCR sequences were identified by NovaSeq (GenomeScan, Leiden, The Netherlands).</p></sec><sec id="s4-8"><title>SARS-CoV-2 infection assay</title><p>Calu-3 lung carcinoma cells (<italic>HTB-55;</italic> ATCC) were cultured in Eagle’s minimum essential medium (Lonza), supplemented with 9% fetal calf serum (CapriCorn Scientific, USA), 1% NEAA (Sigma-Aldrich), 2 mM L-glutamine (Sigma-Aldrich), 1 mM sodium pyruvate (Sigma-Aldrich), and 100 U/ml of penicillin/streptomycin (P/S; Sigma-Aldrich). Calu-3 cells were retrovirally transduced with a pLZRS vector containing the HLA-B*35:01 molecule linked via an internal ribosome entry site sequence to mouse CD19, and transduction was performed as previously described (<xref ref-type="bibr" rid="bib26">Jahn et al., 2015</xref>). Mouse CD19 was used as a marker gene to enrich for successfully transduced cells by adding antibodies directed against mouse CD19 and enriching for stained cells by MACS (Miltenyi) followed by FACS on an Aria III cell sorter (BD Biosciences; see <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref> for antibody details). For the infection assay, Calu-3 cells were seeded in 96-well cell culture plates at a density of 3×10<sup>4</sup> cells per well in 100 μL culture medium. Infections were done with clinical isolate SARS-CoV-2/Leiden-0008, which was isolated from a nasopharyngeal sample collected at the LUMC during the first wave of the Corona pandemic in March 2020 (GenBack: MT705206.1). Cells were infected with SARS-CoV-2 at a MOI of 0.05 or 0.5 in 50 μL infection medium. After 1.5 hr, cells were washed three times with medium, and 100 μL of medium was added. At 6 hr post infection (hpi), medium was removed again, and 100 μL of TCM with 3×10<sup>5</sup> T cells per well was added. At 24 hpi, cells were harvested to collect intracellular RNA by lysing the cells in 100 μL GITC reagent (3 M GITC, 2% sarkosyl, 20 mM Tris, and 20 mM EDTA) per well. Intracellular RNA was isolated using magnetic beads, and viral RNA was quantified by internally controlled multiplex TaqMan RT-quantitative PCR as described previously (<xref ref-type="bibr" rid="bib56">Salgado-Benvindo et al., 2020</xref>).</p></sec><sec id="s4-9"><title>Statistics</title><p>Flow cytometry data was unmixed using Spectroflo (Cytek Biosciences) and analyzed using FlowJo v10.7.1. (BD Biosciences) to set gates on the samples based on the DMSO negative control in ICS assays or adapted to positive control for tetramer staining (see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> for a gating example). Samples were excluded from the analysis if less than 10,000 events in CD4<sup>+</sup> or CD8<sup>+</sup> gate were measured or if after further testing they appeared not to be αβ T cells. For the SARS-CoV-2 infection assays, experiments were excluded from the analysis if the positive control had higher SARS-CoV-2 intracellular RNA copies compared to no T cell condition. Statistical analysis and generation of figures were conducted using GraphPad Prism 9.0.1 (GraphPad Software). Data was tested for significance using an one-way ANOVA with p-values below 0.05 considered as significant. p-Values are categorized in the figures as: ns = not significant; *p&lt;0.05; **p&lt;0.01; or ***p&lt;0.001.</p><p>TCR sequence data was analysed using MiXCR software (v3.0.13) to determine the Vα and Vβ family and CDR3 regions using annotation of the IMGT library (<ext-link ext-link-type="uri" xlink:href="http://www.imgt.org">http://www.imgt.org</ext-link>; v6) (<xref ref-type="bibr" rid="bib10">Bolotin et al., 2015</xref>). CDR3 regions were analysed in RStudio and CDR3 sequences that were non-functional or had ≤50 reads that were excluded from the analysis.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Resources, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Methodology</p></fn><fn fn-type="con" id="con8"><p>Supervision, Methodology</p></fn><fn fn-type="con" id="con9"><p>Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Methodology, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Clinical trial registration NL8589 (Dutch Trial Registry).</p></fn><fn fn-type="other"><p>Human subjects: Bio-banked PBMCs were cryopreserved after informed consent from the respective donors, in accordance with the declaration of Helsinki. The samples from COVID-19 patients were part of a trial (NL8589) registered in the Dutch Trial Registry and approved by Medical Ethical Committee Leiden-Den Haag-Delft (NL73740.058.20).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-82050-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>COVID-19 patient characteristics.</title></caption><media xlink:href="elife-82050-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Cohort characteristics of pre-pandemic samples.</title></caption><media xlink:href="elife-82050-supp2-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>List of peptides.</title></caption><media xlink:href="elife-82050-supp3-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>List of antibodies and reagents used for flow cytometry.</title></caption><media xlink:href="elife-82050-supp4-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>List of primer sequences used for TCR sequencing.</title></caption><media xlink:href="elife-82050-supp5-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Figure 1 - Source data 1 contains percentages underlying figure 1C-F. Figure 4 - Source data 1 contains the sequence data used to generate figures and the data have been deposited in SRA (NCBI) database under BioProjectID PRJNA891934.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Pothast</surname><given-names>CR</given-names></name><name><surname>Hagedoorn</surname><given-names>RS</given-names></name><name><surname>Heemskerk</surname><given-names>MHM</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>TCRa and TCRb sequences of HLA-B*35:01/IPS-isolated T cells</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA891934">PRJNA891934</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors like to thank Joost M Lambooij for critically editing the manuscript. Flow cytometry was performed at the Flow cytometry Core Facility (FCF) of Leiden University Medical Center (LUMC) in Leiden, Netherlands (<ext-link ext-link-type="uri" xlink:href="https://www.lumc.nl/research/facilities/fcf">https://www.lumc.nl/research/facilities/fcf</ext-link>).</p><p>This study was financially supported by Health ~Holland (#LSHM19088) and Australian National Health and Medical Research Council (NHMRC), S.G. is supported by an NHMRC Senior Research Fellowship (#1159272).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Hakeem</surname><given-names>MS</given-names></name><name><surname>Boisvert</surname><given-names>M</given-names></name><name><surname>Bruneau</surname><given-names>J</given-names></name><name><surname>Soudeyns</surname><given-names>H</given-names></name><name><surname>Shoukry</surname><given-names>NH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Selective expansion of high functional avidity memory CD8 T cell clonotypes during hepatitis C virus reinfection and clearance</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006191</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006191</pub-id><pub-id pub-id-type="pmid">28146579</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JJ</given-names></name><name><surname>Narayanan</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Birnbaum</surname><given-names>ME</given-names></name><name><surname>Kruse</surname><given-names>AC</given-names></name><name><surname>Bowerman</surname><given-names>NA</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Levin</surname><given-names>AM</given-names></name><name><surname>Connolly</surname><given-names>JM</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Kranz</surname><given-names>DM</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex</article-title><source>Immunity</source><volume>35</volume><fpage>681</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.09.013</pub-id><pub-id pub-id-type="pmid">22101157</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alanio</surname><given-names>C</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Mathew</surname><given-names>D</given-names></name><name><surname>Gouma</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>G</given-names></name><name><surname>Dunn</surname><given-names>T</given-names></name><name><surname>Oldridge</surname><given-names>DA</given-names></name><name><surname>Weaver</surname><given-names>J</given-names></name><name><surname>Kuri-Cervantes</surname><given-names>L</given-names></name><name><surname>Pampena</surname><given-names>MB</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Collman</surname><given-names>RG</given-names></name><name><surname>Bushman</surname><given-names>FD</given-names></name><name><surname>Meyer</surname><given-names>NJ</given-names></name><name><surname>Hensley</surname><given-names>SE</given-names></name><name><surname>Rader</surname><given-names>D</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Baxter</surname><given-names>AE</given-names></name><name><surname>D’Andrea</surname><given-names>K</given-names></name><name><surname>Adamski</surname><given-names>S</given-names></name><name><surname>Alam</surname><given-names>Z</given-names></name><name><surname>Addison</surname><given-names>MM</given-names></name><name><surname>Byrne</surname><given-names>KT</given-names></name><name><surname>Chandra</surname><given-names>A</given-names></name><name><surname>Descamps</surname><given-names>HC</given-names></name><name><surname>Han</surname><given-names>N</given-names></name><name><surname>Kaminskiy</surname><given-names>Y</given-names></name><name><surname>Kammerman</surname><given-names>SC</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Greenplate</surname><given-names>AR</given-names></name><name><surname>Hamilton</surname><given-names>JT</given-names></name><name><surname>Markosyan</surname><given-names>N</given-names></name><name><surname>Noll</surname><given-names>JH</given-names></name><name><surname>Omran</surname><given-names>DK</given-names></name><name><surname>Pattekar</surname><given-names>A</given-names></name><name><surname>Perkey</surname><given-names>E</given-names></name><name><surname>Prager</surname><given-names>EM</given-names></name><name><surname>Pueschl</surname><given-names>D</given-names></name><name><surname>Rennels</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>JB</given-names></name><name><surname>Shilan</surname><given-names>JS</given-names></name><name><surname>Wilhausen</surname><given-names>N</given-names></name><name><surname>Vanderbeck</surname><given-names>AN</given-names></name><collab>The UPenn COVID Processing Unit</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Cytomegalovirus latent infection is associated with an increased risk of covid-19-related hospitalization</article-title><source>The Journal of Infectious Diseases</source><volume>226</volume><fpage>463</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac020</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreatta</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Gapped sequence alignment using artificial neural networks: application to the MHC class I system</article-title><source>Bioinformatics</source><volume>32</volume><fpage>511</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv639</pub-id><pub-id pub-id-type="pmid">26515819</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacher</surname><given-names>P</given-names></name><name><surname>Rosati</surname><given-names>E</given-names></name><name><surname>Esser</surname><given-names>D</given-names></name><name><surname>Martini</surname><given-names>GR</given-names></name><name><surname>Saggau</surname><given-names>C</given-names></name><name><surname>Schiminsky</surname><given-names>E</given-names></name><name><surname>Dargvainiene</surname><given-names>J</given-names></name><name><surname>Schröder</surname><given-names>I</given-names></name><name><surname>Wieters</surname><given-names>I</given-names></name><name><surname>Khodamoradi</surname><given-names>Y</given-names></name><name><surname>Eberhardt</surname><given-names>F</given-names></name><name><surname>Vehreschild</surname><given-names>M</given-names></name><name><surname>Neb</surname><given-names>H</given-names></name><name><surname>Sonntagbauer</surname><given-names>M</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Tran</surname><given-names>F</given-names></name><name><surname>Rosenstiel</surname><given-names>P</given-names></name><name><surname>Markewitz</surname><given-names>R</given-names></name><name><surname>Wandinger</surname><given-names>KP</given-names></name><name><surname>Augustin</surname><given-names>M</given-names></name><name><surname>Rybniker</surname><given-names>J</given-names></name><name><surname>Kochanek</surname><given-names>M</given-names></name><name><surname>Leypoldt</surname><given-names>F</given-names></name><name><surname>Cornely</surname><given-names>OA</given-names></name><name><surname>Koehler</surname><given-names>P</given-names></name><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>Scheffold</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Low-avidity CD4+ T cell responses to SARS-cov-2 in unexposed individuals and humans with severe COVID-19</article-title><source>Immunity</source><volume>53</volume><fpage>1258</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.11.016</pub-id><pub-id pub-id-type="pmid">33296686</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bange</surname><given-names>EM</given-names></name><name><surname>Han</surname><given-names>NA</given-names></name><name><surname>Wileyto</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Gouma</surname><given-names>S</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Greenplate</surname><given-names>AR</given-names></name><name><surname>Hwee</surname><given-names>MA</given-names></name><name><surname>Porterfield</surname><given-names>F</given-names></name><name><surname>Owoyemi</surname><given-names>O</given-names></name><name><surname>Naik</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>C</given-names></name><name><surname>Galantino</surname><given-names>M</given-names></name><name><surname>Weisman</surname><given-names>AR</given-names></name><name><surname>Ittner</surname><given-names>CAG</given-names></name><name><surname>Kugler</surname><given-names>EM</given-names></name><name><surname>Baxter</surname><given-names>AE</given-names></name><name><surname>Oniyide</surname><given-names>O</given-names></name><name><surname>Agyekum</surname><given-names>RS</given-names></name><name><surname>Dunn</surname><given-names>TG</given-names></name><name><surname>Jones</surname><given-names>TK</given-names></name><name><surname>Giannini</surname><given-names>HM</given-names></name><name><surname>Weirick</surname><given-names>ME</given-names></name><name><surname>McAllister</surname><given-names>CM</given-names></name><name><surname>Babady</surname><given-names>NE</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Widman</surname><given-names>AJ</given-names></name><name><surname>DeWolf</surname><given-names>S</given-names></name><name><surname>Boutemine</surname><given-names>SR</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name><name><surname>Budzik</surname><given-names>KR</given-names></name><name><surname>Tollett</surname><given-names>S</given-names></name><name><surname>Wright</surname><given-names>C</given-names></name><name><surname>Perloff</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Mathew</surname><given-names>D</given-names></name><name><surname>Giles</surname><given-names>JR</given-names></name><name><surname>Oldridge</surname><given-names>DA</given-names></name><name><surname>Wu</surname><given-names>JE</given-names></name><name><surname>Alanio</surname><given-names>C</given-names></name><name><surname>Adamski</surname><given-names>S</given-names></name><name><surname>Garfall</surname><given-names>AL</given-names></name><name><surname>Vella</surname><given-names>LA</given-names></name><name><surname>Kerr</surname><given-names>SJ</given-names></name><name><surname>Cohen</surname><given-names>JV</given-names></name><name><surname>Oyer</surname><given-names>RA</given-names></name><name><surname>Massa</surname><given-names>R</given-names></name><name><surname>Maillard</surname><given-names>IP</given-names></name><name><surname>Maxwell</surname><given-names>KN</given-names></name><name><surname>Reilly</surname><given-names>JP</given-names></name><name><surname>Maslak</surname><given-names>PG</given-names></name><name><surname>Vonderheide</surname><given-names>RH</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Hensley</surname><given-names>SE</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Meyer</surname><given-names>NJ</given-names></name><name><surname>DeMichele</surname><given-names>AM</given-names></name><name><surname>Vardhana</surname><given-names>SA</given-names></name><name><surname>Mamtani</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cd8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer</article-title><source>Nature Medicine</source><volume>27</volume><fpage>1280</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01386-7</pub-id><pub-id pub-id-type="pmid">34017137</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertoletti</surname><given-names>A</given-names></name><name><surname>Le Bert</surname><given-names>N</given-names></name><name><surname>Qui</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-cov-2-specific T cells in infection and vaccination</article-title><source>Cellular &amp; Molecular Immunology</source><volume>18</volume><fpage>2307</fpage><lpage>2312</lpage><pub-id pub-id-type="doi">10.1038/s41423-021-00743-3</pub-id><pub-id pub-id-type="pmid">34471260</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bijen</surname><given-names>HM</given-names></name><name><surname>van der Steen</surname><given-names>DM</given-names></name><name><surname>Hagedoorn</surname><given-names>RS</given-names></name><name><surname>Wouters</surname><given-names>AK</given-names></name><name><surname>Wooldridge</surname><given-names>L</given-names></name><name><surname>Falkenburg</surname><given-names>JHF</given-names></name><name><surname>Heemskerk</surname><given-names>MHM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Preclinical strategies to identify off-target toxicity of high-affinity tcrs</article-title><source>Molecular Therapy</source><volume>26</volume><fpage>1206</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2018.02.017</pub-id><pub-id pub-id-type="pmid">29567312</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birnbaum</surname><given-names>ME</given-names></name><name><surname>Mendoza</surname><given-names>JL</given-names></name><name><surname>Sethi</surname><given-names>DK</given-names></name><name><surname>Dong</surname><given-names>S</given-names></name><name><surname>Glanville</surname><given-names>J</given-names></name><name><surname>Dobbins</surname><given-names>J</given-names></name><name><surname>Ozkan</surname><given-names>E</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name><name><surname>Wucherpfennig</surname><given-names>KW</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Deconstructing the peptide-MHC specificity of T cell recognition</article-title><source>Cell</source><volume>157</volume><fpage>1073</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.03.047</pub-id><pub-id pub-id-type="pmid">24855945</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolotin</surname><given-names>DA</given-names></name><name><surname>Poslavsky</surname><given-names>S</given-names></name><name><surname>Mitrophanov</surname><given-names>I</given-names></name><name><surname>Shugay</surname><given-names>M</given-names></name><name><surname>Mamedov</surname><given-names>IZ</given-names></name><name><surname>Putintseva</surname><given-names>EV</given-names></name><name><surname>Chudakov</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MiXCR: software for comprehensive adaptive immunity profiling</article-title><source>Nature Methods</source><volume>12</volume><fpage>380</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3364</pub-id><pub-id pub-id-type="pmid">25924071</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Loyal</surname><given-names>L</given-names></name><name><surname>Frentsch</surname><given-names>M</given-names></name><name><surname>Wendisch</surname><given-names>D</given-names></name><name><surname>Georg</surname><given-names>P</given-names></name><name><surname>Kurth</surname><given-names>F</given-names></name><name><surname>Hippenstiel</surname><given-names>S</given-names></name><name><surname>Dingeldey</surname><given-names>M</given-names></name><name><surname>Kruse</surname><given-names>B</given-names></name><name><surname>Fauchere</surname><given-names>F</given-names></name><name><surname>Baysal</surname><given-names>E</given-names></name><name><surname>Mangold</surname><given-names>M</given-names></name><name><surname>Henze</surname><given-names>L</given-names></name><name><surname>Lauster</surname><given-names>R</given-names></name><name><surname>Mall</surname><given-names>MA</given-names></name><name><surname>Beyer</surname><given-names>K</given-names></name><name><surname>Röhmel</surname><given-names>J</given-names></name><name><surname>Voigt</surname><given-names>S</given-names></name><name><surname>Schmitz</surname><given-names>J</given-names></name><name><surname>Miltenyi</surname><given-names>S</given-names></name><name><surname>Demuth</surname><given-names>I</given-names></name><name><surname>Müller</surname><given-names>MA</given-names></name><name><surname>Hocke</surname><given-names>A</given-names></name><name><surname>Witzenrath</surname><given-names>M</given-names></name><name><surname>Suttorp</surname><given-names>N</given-names></name><name><surname>Kern</surname><given-names>F</given-names></name><name><surname>Reimer</surname><given-names>U</given-names></name><name><surname>Wenschuh</surname><given-names>H</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Giesecke-Thiel</surname><given-names>C</given-names></name><name><surname>Sander</surname><given-names>LE</given-names></name><name><surname>Thiel</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-cov-2-reactive T cells in healthy donors and patients with COVID-19</article-title><source>Nature</source><volume>587</volume><fpage>270</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2598-9</pub-id><pub-id pub-id-type="pmid">32726801</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodin</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Immune determinants of COVID-19 disease presentation and severity</article-title><source>Nature Medicine</source><volume>27</volume><fpage>28</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-01202-8</pub-id><pub-id pub-id-type="pmid">33442016</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>BJ</given-names></name><name><surname>Gerry</surname><given-names>AB</given-names></name><name><surname>Dukes</surname><given-names>J</given-names></name><name><surname>Harper</surname><given-names>JV</given-names></name><name><surname>Kannan</surname><given-names>V</given-names></name><name><surname>Bianchi</surname><given-names>FC</given-names></name><name><surname>Grand</surname><given-names>F</given-names></name><name><surname>Brewer</surname><given-names>JE</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Plesa</surname><given-names>G</given-names></name><name><surname>Bossi</surname><given-names>G</given-names></name><name><surname>Vuidepot</surname><given-names>A</given-names></name><name><surname>Powlesland</surname><given-names>AS</given-names></name><name><surname>Legg</surname><given-names>A</given-names></name><name><surname>Adams</surname><given-names>KJ</given-names></name><name><surname>Bennett</surname><given-names>AD</given-names></name><name><surname>Pumphrey</surname><given-names>NJ</given-names></name><name><surname>Williams</surname><given-names>DD</given-names></name><name><surname>Binder-Scholl</surname><given-names>G</given-names></name><name><surname>Kulikovskaya</surname><given-names>I</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Riley</surname><given-names>JL</given-names></name><name><surname>Varela-Rohena</surname><given-names>A</given-names></name><name><surname>Stadtmauer</surname><given-names>EA</given-names></name><name><surname>Rapoport</surname><given-names>AP</given-names></name><name><surname>Linette</surname><given-names>GP</given-names></name><name><surname>June</surname><given-names>CH</given-names></name><name><surname>Hassan</surname><given-names>NJ</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Jakobsen</surname><given-names>BK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells</article-title><source>Science Translational Medicine</source><volume>5</volume><elocation-id>197ra103</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3006034</pub-id><pub-id pub-id-type="pmid">23926201</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiuppesi</surname><given-names>F</given-names></name><name><surname>Zaia</surname><given-names>JA</given-names></name><name><surname>Faircloth</surname><given-names>K</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Ly</surname><given-names>M</given-names></name><name><surname>Karpinski</surname><given-names>V</given-names></name><name><surname>La Rosa</surname><given-names>C</given-names></name><name><surname>Drake</surname><given-names>J</given-names></name><name><surname>Marcia</surname><given-names>J</given-names></name><name><surname>Acosta</surname><given-names>AM</given-names></name><name><surname>Dempsey</surname><given-names>S</given-names></name><name><surname>Taplitz</surname><given-names>RA</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Ortega Francisco</surname><given-names>S</given-names></name><name><surname>Kaltcheva</surname><given-names>T</given-names></name><name><surname>Frankel</surname><given-names>PH</given-names></name><name><surname>Rosen</surname><given-names>S</given-names></name><name><surname>Wussow</surname><given-names>F</given-names></name><name><surname>Dadwal</surname><given-names>S</given-names></name><name><surname>Diamond</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-cov-2 delta and omicron variants</article-title><source>IScience</source><volume>25</volume><elocation-id>104745</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2022.104745</pub-id><pub-id pub-id-type="pmid">35846380</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>DU</given-names></name><name><surname>Noh</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Jeong</surname><given-names>HW</given-names></name><name><surname>Shin</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>T cell epitopes in SARS-cov-2 proteins are substantially conserved in the omicron variant</article-title><source>Cellular &amp; Molecular Immunology</source><volume>19</volume><fpage>447</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1038/s41423-022-00838-5</pub-id><pub-id pub-id-type="pmid">35043006</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clute</surname><given-names>SC</given-names></name><name><surname>Watkin</surname><given-names>LB</given-names></name><name><surname>Cornberg</surname><given-names>M</given-names></name><name><surname>Naumov</surname><given-names>YN</given-names></name><name><surname>Sullivan</surname><given-names>JL</given-names></name><name><surname>Luzuriaga</surname><given-names>K</given-names></name><name><surname>Welsh</surname><given-names>RM</given-names></name><name><surname>Selin</surname><given-names>LK</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in epstein-barr virus-associated infectious mononucleosis</article-title><source>The Journal of Clinical Investigation</source><volume>115</volume><fpage>3602</fpage><lpage>3612</lpage><pub-id pub-id-type="doi">10.1172/JCI25078</pub-id><pub-id pub-id-type="pmid">16308574</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>DK</given-names></name><name><surname>Bulek</surname><given-names>AM</given-names></name><name><surname>Dolton</surname><given-names>G</given-names></name><name><surname>Schauenberg</surname><given-names>AJ</given-names></name><name><surname>Szomolay</surname><given-names>B</given-names></name><name><surname>Rittase</surname><given-names>W</given-names></name><name><surname>Trimby</surname><given-names>A</given-names></name><name><surname>Jothikumar</surname><given-names>P</given-names></name><name><surname>Fuller</surname><given-names>A</given-names></name><name><surname>Skowera</surname><given-names>A</given-names></name><name><surname>Rossjohn</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Miles</surname><given-names>JJ</given-names></name><name><surname>Peakman</surname><given-names>M</given-names></name><name><surname>Wooldridge</surname><given-names>L</given-names></name><name><surname>Rizkallah</surname><given-names>PJ</given-names></name><name><surname>Sewell</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity</article-title><source>The Journal of Clinical Investigation</source><volume>126</volume><elocation-id>3626</elocation-id><pub-id pub-id-type="doi">10.1172/JCI89919</pub-id><pub-id pub-id-type="pmid">27525441</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornberg</surname><given-names>M</given-names></name><name><surname>Clute</surname><given-names>SC</given-names></name><name><surname>Watkin</surname><given-names>LB</given-names></name><name><surname>Saccoccio</surname><given-names>FM</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Naumov</surname><given-names>YN</given-names></name><name><surname>Brehm</surname><given-names>MA</given-names></name><name><surname>Aslan</surname><given-names>N</given-names></name><name><surname>Welsh</surname><given-names>RM</given-names></name><name><surname>Selin</surname><given-names>LK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cd8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infections</article-title><source>Journal of Immunology</source><volume>184</volume><fpage>2825</fpage><lpage>2838</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0902168</pub-id><pub-id pub-id-type="pmid">20164414</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cusick</surname><given-names>MF</given-names></name><name><surname>Libbey</surname><given-names>JE</given-names></name><name><surname>Fujinami</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Molecular mimicry as a mechanism of autoimmune disease</article-title><source>Clinical Reviews in Allergy &amp; Immunology</source><volume>42</volume><fpage>102</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1007/s12016-011-8293-8</pub-id><pub-id pub-id-type="pmid">22095454</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escobar</surname><given-names>H</given-names></name><name><surname>Crockett</surname><given-names>DK</given-names></name><name><surname>Reyes-Vargas</surname><given-names>E</given-names></name><name><surname>Baena</surname><given-names>A</given-names></name><name><surname>Rockwood</surname><given-names>AL</given-names></name><name><surname>Jensen</surname><given-names>PE</given-names></name><name><surname>Delgado</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Large scale mass spectrometric profiling of peptides eluted from HLA molecules reveals N-terminal-extended peptide motifs</article-title><source>Journal of Immunology</source><volume>181</volume><fpage>4874</fpage><lpage>4882</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.7.4874</pub-id><pub-id pub-id-type="pmid">18802091</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A systematic review of asymptomatic infections with COVID-19</article-title><source>Journal of Microbiology, Immunology and Infection</source><volume>54</volume><fpage>12</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.jmii.2020.05.001</pub-id><pub-id pub-id-type="pmid">32425996</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>C</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>TR</given-names></name><name><surname>Niessl</surname><given-names>J</given-names></name><name><surname>Olofsson</surname><given-names>A</given-names></name><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Hansson</surname><given-names>L</given-names></name><name><surname>Österborg</surname><given-names>A</given-names></name><name><surname>Bergman</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Olsson</surname><given-names>A</given-names></name><name><surname>Sandberg</surname><given-names>JK</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name><name><surname>Karlsson</surname><given-names>AC</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Aleman</surname><given-names>S</given-names></name><name><surname>Buggert</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Ancestral SARS-cov-2-specific T cells cross-recognize the omicron variant</article-title><source>Nature Medicine</source><volume>28</volume><fpage>472</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01700-x</pub-id><pub-id pub-id-type="pmid">35042228</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>GeurtsvanKessel</surname><given-names>CH</given-names></name><name><surname>Geers</surname><given-names>D</given-names></name><name><surname>Schmitz</surname><given-names>KS</given-names></name><name><surname>Mykytyn</surname><given-names>AZ</given-names></name><name><surname>Lamers</surname><given-names>MM</given-names></name><name><surname>Bogers</surname><given-names>S</given-names></name><name><surname>Scherbeijn</surname><given-names>S</given-names></name><name><surname>Gommers</surname><given-names>L</given-names></name><name><surname>Sablerolles</surname><given-names>RSG</given-names></name><name><surname>Nieuwkoop</surname><given-names>NN</given-names></name><name><surname>Rijsbergen</surname><given-names>LC</given-names></name><name><surname>van Dijk</surname><given-names>LLA</given-names></name><name><surname>de Wilde</surname><given-names>J</given-names></name><name><surname>Alblas</surname><given-names>K</given-names></name><name><surname>Breugem</surname><given-names>TI</given-names></name><name><surname>Rijnders</surname><given-names>BJA</given-names></name><name><surname>de Jager</surname><given-names>H</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>van der Kuy</surname><given-names>PHM</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Koopmans</surname><given-names>MPG</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Haagmans</surname><given-names>BL</given-names></name><name><surname>de Vries</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Divergent SARS-cov-2 omicron–reactive T and B cell responses in COVID-19 vaccine recipients</article-title><source>Science Immunology</source><volume>7</volume><elocation-id>abo2202</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abo2202</pub-id><pub-id pub-id-type="pmid">35113647</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Moderbacher</surname><given-names>CR</given-names></name><name><surname>Rawlings</surname><given-names>SA</given-names></name><name><surname>Sutherland</surname><given-names>A</given-names></name><name><surname>Premkumar</surname><given-names>L</given-names></name><name><surname>Jadi</surname><given-names>RS</given-names></name><name><surname>Marrama</surname><given-names>D</given-names></name><name><surname>de Silva</surname><given-names>AM</given-names></name><name><surname>Frazier</surname><given-names>A</given-names></name><name><surname>Carlin</surname><given-names>AF</given-names></name><name><surname>Greenbaum</surname><given-names>JA</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targets of T cell responses to SARS-cov-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title><source>Cell</source><volume>181</volume><fpage>1489</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.015</pub-id><pub-id pub-id-type="pmid">32473127</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hombrink</surname><given-names>P</given-names></name><name><surname>Raz</surname><given-names>Y</given-names></name><name><surname>Kester</surname><given-names>MGD</given-names></name><name><surname>de Boer</surname><given-names>R</given-names></name><name><surname>Weißbrich</surname><given-names>B</given-names></name><name><surname>von dem Borne</surname><given-names>PA</given-names></name><name><surname>Busch</surname><given-names>DH</given-names></name><name><surname>Schumacher</surname><given-names>TNM</given-names></name><name><surname>Falkenburg</surname><given-names>JHF</given-names></name><name><surname>Heemskerk</surname><given-names>MHM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mixed functional characteristics correlating with TCR-ligand K off -rate of MHC-tetramer reactive T cells within the naive T-cell repertoire</article-title><source>European Journal of Immunology</source><volume>43</volume><fpage>3038</fpage><lpage>3050</lpage><pub-id pub-id-type="doi">10.1002/eji.201343397</pub-id><pub-id pub-id-type="pmid">23893393</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahn</surname><given-names>L</given-names></name><name><surname>Hombrink</surname><given-names>P</given-names></name><name><surname>Hassan</surname><given-names>C</given-names></name><name><surname>Kester</surname><given-names>MGD</given-names></name><name><surname>van der Steen</surname><given-names>DM</given-names></name><name><surname>Hagedoorn</surname><given-names>RS</given-names></name><name><surname>Falkenburg</surname><given-names>JHF</given-names></name><name><surname>van Veelen</surname><given-names>PA</given-names></name><name><surname>Heemskerk</surname><given-names>MHM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Therapeutic targeting of the BCR-associated protein cd79b in a TCR-based approach is hampered by aberrant expression of cd79b</article-title><source>Blood</source><volume>125</volume><fpage>949</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-07-587840</pub-id><pub-id pub-id-type="pmid">25414443</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Ueno</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Nagao</surname><given-names>M</given-names></name><name><surname>Yamanaka</surname><given-names>S</given-names></name><name><surname>Hamazaki</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Aging and CMV infection affect pre-existing SARS-cov-2-reactive CD8<sup>+</sup> T cells in unexposed individuals</article-title><source>Frontiers in Aging</source><volume>2</volume><elocation-id>719342</elocation-id><pub-id pub-id-type="doi">10.3389/fragi.2021.719342</pub-id><pub-id pub-id-type="pmid">35822004</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>AM</given-names></name><name><surname>Malhotra</surname><given-names>U</given-names></name><name><surname>Kim</surname><given-names>YG</given-names></name><name><surname>Gomez</surname><given-names>R</given-names></name><name><surname>Krist</surname><given-names>MP</given-names></name><name><surname>Wald</surname><given-names>A</given-names></name><name><surname>Koelle</surname><given-names>DM</given-names></name><name><surname>Kwok</surname><given-names>WW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cross-reactive and mono-reactive SARS-cov-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals</article-title><source>PLOS Pathogens</source><volume>17</volume><elocation-id>e1010203</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1010203</pub-id><pub-id pub-id-type="pmid">34965282</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>MK</given-names></name><name><surname>Jeong</surname><given-names>SD</given-names></name><name><surname>Noh</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>DU</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>JY</given-names></name><name><surname>Jeong</surname><given-names>HW</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Shin</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>BNT162b2-induced memory T cells respond to the omicron variant with preserved polyfunctionality</article-title><source>Nature Microbiology</source><volume>7</volume><fpage>909</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1038/s41564-022-01123-x</pub-id><pub-id pub-id-type="pmid">35577972</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keeton</surname><given-names>R</given-names></name><name><surname>Tincho</surname><given-names>MB</given-names></name><name><surname>Ngomti</surname><given-names>A</given-names></name><name><surname>Baguma</surname><given-names>R</given-names></name><name><surname>Benede</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Cele</surname><given-names>S</given-names></name><name><surname>Bernstein</surname><given-names>M</given-names></name><name><surname>Karim</surname><given-names>F</given-names></name><name><surname>Madzorera</surname><given-names>SV</given-names></name><name><surname>Moyo-Gwete</surname><given-names>T</given-names></name><name><surname>Mennen</surname><given-names>M</given-names></name><name><surname>Skelem</surname><given-names>S</given-names></name><name><surname>Adriaanse</surname><given-names>M</given-names></name><name><surname>Mutithu</surname><given-names>D</given-names></name><name><surname>Aremu</surname><given-names>O</given-names></name><name><surname>Stek</surname><given-names>C</given-names></name><name><surname>du Bruyn</surname><given-names>E</given-names></name><name><surname>Van Der Mescht</surname><given-names>MA</given-names></name><name><surname>de Beer</surname><given-names>Z</given-names></name><name><surname>de Villiers</surname><given-names>TR</given-names></name><name><surname>Bodenstein</surname><given-names>A</given-names></name><name><surname>van den Berg</surname><given-names>G</given-names></name><name><surname>Mendes</surname><given-names>A</given-names></name><name><surname>Strydom</surname><given-names>A</given-names></name><name><surname>Venter</surname><given-names>M</given-names></name><name><surname>Giandhari</surname><given-names>J</given-names></name><name><surname>Naidoo</surname><given-names>Y</given-names></name><name><surname>Pillay</surname><given-names>S</given-names></name><name><surname>Tegally</surname><given-names>H</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>de Oliveira</surname><given-names>T</given-names></name><name><surname>Bekker</surname><given-names>LG</given-names></name><name><surname>Gray</surname><given-names>G</given-names></name><name><surname>Ueckermann</surname><given-names>V</given-names></name><name><surname>Rossouw</surname><given-names>T</given-names></name><name><surname>Boswell</surname><given-names>MT</given-names></name><name><surname>Bhiman</surname><given-names>JN</given-names></name><name><surname>Moore</surname><given-names>PL</given-names></name><name><surname>Sigal</surname><given-names>A</given-names></name><name><surname>Ntusi</surname><given-names>NAB</given-names></name><name><surname>Burgers</surname><given-names>WA</given-names></name><name><surname>Riou</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>T cell responses to SARS-cov-2 spike cross-recognize omicron</article-title><source>Nature</source><volume>603</volume><fpage>488</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04460-3</pub-id><pub-id pub-id-type="pmid">35102311</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klarenbeek</surname><given-names>PL</given-names></name><name><surname>Remmerswaal</surname><given-names>EBM</given-names></name><name><surname>ten Berge</surname><given-names>IJM</given-names></name><name><surname>Doorenspleet</surname><given-names>ME</given-names></name><name><surname>van Schaik</surname><given-names>BDC</given-names></name><name><surname>Esveldt</surname><given-names>REE</given-names></name><name><surname>Koch</surname><given-names>SD</given-names></name><name><surname>ten Brinke</surname><given-names>A</given-names></name><name><surname>van Kampen</surname><given-names>AHC</given-names></name><name><surname>Bemelman</surname><given-names>FJ</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Baas</surname><given-names>F</given-names></name><name><surname>de Vries</surname><given-names>N</given-names></name><name><surname>van Lier</surname><given-names>RAW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Deep sequencing of antiviral T-cell responses to HCMV and EBV in humans reveals a stable repertoire that is maintained for many years</article-title><source>PLOS Pathogens</source><volume>8</volume><elocation-id>e1002889</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002889</pub-id><pub-id pub-id-type="pmid">23028307</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koning</surname><given-names>MT</given-names></name><name><surname>Kiełbasa</surname><given-names>SM</given-names></name><name><surname>Boersma</surname><given-names>V</given-names></name><name><surname>Buermans</surname><given-names>HPJ</given-names></name><name><surname>van der Zeeuw</surname><given-names>SAJ</given-names></name><name><surname>van Bergen</surname><given-names>CAM</given-names></name><name><surname>Cleven</surname><given-names>AHG</given-names></name><name><surname>Kluin</surname><given-names>PM</given-names></name><name><surname>Griffioen</surname><given-names>M</given-names></name><name><surname>Navarrete</surname><given-names>MA</given-names></name><name><surname>Veelken</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Artisan PCR: rapid identification of full-length immunoglobulin rearrangements without primer binding bias</article-title><source>British Journal of Haematology</source><volume>178</volume><fpage>983</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1111/bjh.14180</pub-id><pub-id pub-id-type="pmid">27301611</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kundu</surname><given-names>R</given-names></name><name><surname>Narean</surname><given-names>JS</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Fenn</surname><given-names>J</given-names></name><name><surname>Pillay</surname><given-names>T</given-names></name><name><surname>Fernandez</surname><given-names>ND</given-names></name><name><surname>Conibear</surname><given-names>E</given-names></name><name><surname>Koycheva</surname><given-names>A</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name><name><surname>Tolosa-Wright</surname><given-names>M</given-names></name><name><surname>Hakki</surname><given-names>S</given-names></name><name><surname>Varro</surname><given-names>R</given-names></name><name><surname>McDermott</surname><given-names>E</given-names></name><name><surname>Hammett</surname><given-names>S</given-names></name><name><surname>Cutajar</surname><given-names>J</given-names></name><name><surname>Thwaites</surname><given-names>RS</given-names></name><name><surname>Parker</surname><given-names>E</given-names></name><name><surname>Rosadas</surname><given-names>C</given-names></name><name><surname>McClure</surname><given-names>M</given-names></name><name><surname>Tedder</surname><given-names>R</given-names></name><name><surname>Taylor</surname><given-names>GP</given-names></name><name><surname>Dunning</surname><given-names>J</given-names></name><name><surname>Lalvani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cross-reactive memory T cells associate with protection against SARS-cov-2 infection in COVID-19 contacts</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>80</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-27674-x</pub-id><pub-id pub-id-type="pmid">35013199</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bert</surname><given-names>N</given-names></name><name><surname>Tan</surname><given-names>AT</given-names></name><name><surname>Kunasegaran</surname><given-names>K</given-names></name><name><surname>Tham</surname><given-names>CYL</given-names></name><name><surname>Hafezi</surname><given-names>M</given-names></name><name><surname>Chia</surname><given-names>A</given-names></name><name><surname>Chng</surname><given-names>MHY</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>N</given-names></name><name><surname>Linster</surname><given-names>M</given-names></name><name><surname>Chia</surname><given-names>WN</given-names></name><name><surname>Chen</surname><given-names>MIC</given-names></name><name><surname>Wang</surname><given-names>LF</given-names></name><name><surname>Ooi</surname><given-names>EE</given-names></name><name><surname>Kalimuddin</surname><given-names>S</given-names></name><name><surname>Tambyah</surname><given-names>PA</given-names></name><name><surname>Low</surname><given-names>JGH</given-names></name><name><surname>Tan</surname><given-names>YJ</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-cov-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</article-title><source>Nature</source><volume>584</volume><fpage>457</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2550-z</pub-id><pub-id pub-id-type="pmid">32668444</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Salio</surname><given-names>M</given-names></name><name><surname>Napolitani</surname><given-names>G</given-names></name><name><surname>Ogg</surname><given-names>G</given-names></name><name><surname>Simmons</surname><given-names>A</given-names></name><name><surname>Koohy</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Predicting cross-reactivity and antigen specificity of T cell receptors</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>565096</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.565096</pub-id><pub-id pub-id-type="pmid">33193332</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19</article-title><source>Nature Medicine</source><volume>26</volume><fpage>842</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0901-9</pub-id><pub-id pub-id-type="pmid">32398875</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lineburg</surname><given-names>KE</given-names></name><name><surname>Grant</surname><given-names>EJ</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name><name><surname>Chatzileontiadou</surname><given-names>DSM</given-names></name><name><surname>Szeto</surname><given-names>C</given-names></name><name><surname>Sloane</surname><given-names>H</given-names></name><name><surname>Panikkar</surname><given-names>A</given-names></name><name><surname>Raju</surname><given-names>J</given-names></name><name><surname>Crooks</surname><given-names>P</given-names></name><name><surname>Rehan</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>AT</given-names></name><name><surname>Lekieffre</surname><given-names>L</given-names></name><name><surname>Neller</surname><given-names>MA</given-names></name><name><surname>Tong</surname><given-names>ZWM</given-names></name><name><surname>Jayasinghe</surname><given-names>D</given-names></name><name><surname>Chew</surname><given-names>KY</given-names></name><name><surname>Lobos</surname><given-names>CA</given-names></name><name><surname>Halim</surname><given-names>H</given-names></name><name><surname>Burrows</surname><given-names>JM</given-names></name><name><surname>Riboldi-Tunnicliffe</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>D’Orsogna</surname><given-names>L</given-names></name><name><surname>Khanna</surname><given-names>R</given-names></name><name><surname>Short</surname><given-names>KR</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Gras</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cd8+ T cells specific for an immunodominant SARS-cov-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses</article-title><source>Immunity</source><volume>54</volume><fpage>1055</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.04.006</pub-id><pub-id pub-id-type="pmid">33945786</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Chandrashekar</surname><given-names>A</given-names></name><name><surname>Sellers</surname><given-names>D</given-names></name><name><surname>Barrett</surname><given-names>J</given-names></name><name><surname>Jacob-Dolan</surname><given-names>C</given-names></name><name><surname>Lifton</surname><given-names>M</given-names></name><name><surname>McMahan</surname><given-names>K</given-names></name><name><surname>Sciacca</surname><given-names>M</given-names></name><name><surname>VanWyk</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Collier</surname><given-names>ARY</given-names></name><name><surname>Barouch</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Vaccines elicit highly conserved cellular immunity to SARS-cov-2 omicron</article-title><source>Nature</source><volume>603</volume><fpage>493</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04465-y</pub-id><pub-id pub-id-type="pmid">35102312</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loyal</surname><given-names>L</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Henze</surname><given-names>L</given-names></name><name><surname>Kruse</surname><given-names>B</given-names></name><name><surname>Dingeldey</surname><given-names>M</given-names></name><name><surname>Reimer</surname><given-names>U</given-names></name><name><surname>Kern</surname><given-names>F</given-names></name><name><surname>Schwarz</surname><given-names>T</given-names></name><name><surname>Mangold</surname><given-names>M</given-names></name><name><surname>Unger</surname><given-names>C</given-names></name><name><surname>Dörfler</surname><given-names>F</given-names></name><name><surname>Kadler</surname><given-names>S</given-names></name><name><surname>Rosowski</surname><given-names>J</given-names></name><name><surname>Gürcan</surname><given-names>K</given-names></name><name><surname>Uyar-Aydin</surname><given-names>Z</given-names></name><name><surname>Frentsch</surname><given-names>M</given-names></name><name><surname>Kurth</surname><given-names>F</given-names></name><name><surname>Schnatbaum</surname><given-names>K</given-names></name><name><surname>Eckey</surname><given-names>M</given-names></name><name><surname>Hippenstiel</surname><given-names>S</given-names></name><name><surname>Hocke</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>MA</given-names></name><name><surname>Sawitzki</surname><given-names>B</given-names></name><name><surname>Miltenyi</surname><given-names>S</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name><name><surname>Mall</surname><given-names>MA</given-names></name><name><surname>Wenschuh</surname><given-names>H</given-names></name><name><surname>Voigt</surname><given-names>S</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Lauster</surname><given-names>R</given-names></name><name><surname>Lachman</surname><given-names>N</given-names></name><name><surname>Sander</surname><given-names>LE</given-names></name><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Röhmel</surname><given-names>J</given-names></name><name><surname>Meyer-Arndt</surname><given-names>L</given-names></name><name><surname>Thiel</surname><given-names>A</given-names></name><name><surname>Giesecke-Thiel</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cross-reactive CD4+ T cells enhance SARS-cov-2 immune responses upon infection and vaccination</article-title><source>Science</source><volume>374</volume><elocation-id>eabh1823</elocation-id><pub-id pub-id-type="doi">10.1126/science.abh1823</pub-id><pub-id pub-id-type="pmid">34465633</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>WA</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Gras</surname><given-names>S</given-names></name><name><surname>Archbold</surname><given-names>JK</given-names></name><name><surname>Tynan</surname><given-names>FE</given-names></name><name><surname>Clements</surname><given-names>CS</given-names></name><name><surname>Bharadwaj</surname><given-names>M</given-names></name><name><surname>Kjer-Nielsen</surname><given-names>L</given-names></name><name><surname>Saunders</surname><given-names>PM</given-names></name><name><surname>Wilce</surname><given-names>MCJ</given-names></name><name><surname>Crawford</surname><given-names>F</given-names></name><name><surname>Stadinsky</surname><given-names>B</given-names></name><name><surname>Jackson</surname><given-names>D</given-names></name><name><surname>Brooks</surname><given-names>AG</given-names></name><name><surname>Purcell</surname><given-names>AW</given-names></name><name><surname>Kappler</surname><given-names>JW</given-names></name><name><surname>Burrows</surname><given-names>SR</given-names></name><name><surname>Rossjohn</surname><given-names>J</given-names></name><name><surname>McCluskey</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>T cell allorecognition via molecular mimicry</article-title><source>Immunity</source><volume>31</volume><fpage>897</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.09.025</pub-id><pub-id pub-id-type="pmid">20064448</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Tarke</surname><given-names>A</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Burger</surname><given-names>ZC</given-names></name><name><surname>Rawlings</surname><given-names>SA</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Phillips</surname><given-names>E</given-names></name><name><surname>Mallal</surname><given-names>S</given-names></name><name><surname>Lammers</surname><given-names>M</given-names></name><name><surname>Rubiro</surname><given-names>P</given-names></name><name><surname>Quiambao</surname><given-names>L</given-names></name><name><surname>Sutherland</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>ED</given-names></name><name><surname>da Silva Antunes</surname><given-names>R</given-names></name><name><surname>Greenbaum</surname><given-names>J</given-names></name><name><surname>Frazier</surname><given-names>A</given-names></name><name><surname>Markmann</surname><given-names>AJ</given-names></name><name><surname>Premkumar</surname><given-names>L</given-names></name><name><surname>de Silva</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Selective and cross-reactive SARS-cov-2 T cell epitopes in unexposed humans</article-title><source>Science</source><volume>370</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1126/science.abd3871</pub-id><pub-id pub-id-type="pmid">32753554</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meckiff</surname><given-names>BJ</given-names></name><name><surname>Ramírez-Suástegui</surname><given-names>C</given-names></name><name><surname>Fajardo</surname><given-names>V</given-names></name><name><surname>Chee</surname><given-names>SJ</given-names></name><name><surname>Kusnadi</surname><given-names>A</given-names></name><name><surname>Simon</surname><given-names>H</given-names></name><name><surname>Eschweiler</surname><given-names>S</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Pelosi</surname><given-names>E</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Ay</surname><given-names>F</given-names></name><name><surname>Seumois</surname><given-names>G</given-names></name><name><surname>Ottensmeier</surname><given-names>CH</given-names></name><name><surname>Vijayanand</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Imbalance of regulatory and cytotoxic SARS-cov-2-reactive CD4+ T cells in COVID-19</article-title><source>Cell</source><volume>183</volume><fpage>1340</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.10.001</pub-id><pub-id pub-id-type="pmid">33096020</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morton</surname><given-names>LT</given-names></name><name><surname>Reijmers</surname><given-names>RM</given-names></name><name><surname>Wouters</surname><given-names>AK</given-names></name><name><surname>Kweekel</surname><given-names>C</given-names></name><name><surname>Remst</surname><given-names>DFG</given-names></name><name><surname>Pothast</surname><given-names>CR</given-names></name><name><surname>Falkenburg</surname><given-names>JHF</given-names></name><name><surname>Heemskerk</surname><given-names>MHM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Simultaneous deletion of endogenous TCRαβ for TCR gene therapy creates an improved and safe cellular therapeutic</article-title><source>Molecular Therapy</source><volume>28</volume><fpage>64</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.10.001</pub-id><pub-id pub-id-type="pmid">31636040</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelde</surname><given-names>A</given-names></name><name><surname>Bilich</surname><given-names>T</given-names></name><name><surname>Heitmann</surname><given-names>JS</given-names></name><name><surname>Maringer</surname><given-names>Y</given-names></name><name><surname>Salih</surname><given-names>HR</given-names></name><name><surname>Roerden</surname><given-names>M</given-names></name><name><surname>Lübke</surname><given-names>M</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Rieth</surname><given-names>J</given-names></name><name><surname>Wacker</surname><given-names>M</given-names></name><name><surname>Peter</surname><given-names>A</given-names></name><name><surname>Hörber</surname><given-names>S</given-names></name><name><surname>Traenkle</surname><given-names>B</given-names></name><name><surname>Kaiser</surname><given-names>PD</given-names></name><name><surname>Rothbauer</surname><given-names>U</given-names></name><name><surname>Becker</surname><given-names>M</given-names></name><name><surname>Junker</surname><given-names>D</given-names></name><name><surname>Krause</surname><given-names>G</given-names></name><name><surname>Strengert</surname><given-names>M</given-names></name><name><surname>Schneiderhan-Marra</surname><given-names>N</given-names></name><name><surname>Templin</surname><given-names>MF</given-names></name><name><surname>Joos</surname><given-names>TO</given-names></name><name><surname>Kowalewski</surname><given-names>DJ</given-names></name><name><surname>Stos-Zweifel</surname><given-names>V</given-names></name><name><surname>Fehr</surname><given-names>M</given-names></name><name><surname>Rabsteyn</surname><given-names>A</given-names></name><name><surname>Mirakaj</surname><given-names>V</given-names></name><name><surname>Karbach</surname><given-names>J</given-names></name><name><surname>Jäger</surname><given-names>E</given-names></name><name><surname>Graf</surname><given-names>M</given-names></name><name><surname>Gruber</surname><given-names>LC</given-names></name><name><surname>Rachfalski</surname><given-names>D</given-names></name><name><surname>Preuß</surname><given-names>B</given-names></name><name><surname>Hagelstein</surname><given-names>I</given-names></name><name><surname>Märklin</surname><given-names>M</given-names></name><name><surname>Bakchoul</surname><given-names>T</given-names></name><name><surname>Gouttefangeas</surname><given-names>C</given-names></name><name><surname>Kohlbacher</surname><given-names>O</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Stevanović</surname><given-names>S</given-names></name><name><surname>Rammensee</surname><given-names>HG</given-names></name><name><surname>Walz</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-cov-2-derived peptides define heterologous and COVID-19-induced T cell recognition</article-title><source>Nature Immunology</source><volume>22</volume><fpage>74</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-00808-x</pub-id><pub-id pub-id-type="pmid">32999467</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>AT</given-names></name><name><surname>Szeto</surname><given-names>C</given-names></name><name><surname>Jayasinghe</surname><given-names>D</given-names></name><name><surname>Lobos</surname><given-names>CA</given-names></name><name><surname>Halim</surname><given-names>H</given-names></name><name><surname>Chatzileontiadou</surname><given-names>DSM</given-names></name><name><surname>Grant</surname><given-names>EJ</given-names></name><name><surname>Gras</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-cov-2 spike-derived peptides presented by HLA molecules</article-title><source>Biophysica</source><volume>1</volume><fpage>194</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.3390/biophysica1020015</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellicci</surname><given-names>DG</given-names></name><name><surname>Uldrich</surname><given-names>AP</given-names></name><name><surname>Le Nours</surname><given-names>J</given-names></name><name><surname>Ross</surname><given-names>F</given-names></name><name><surname>Chabrol</surname><given-names>E</given-names></name><name><surname>Eckle</surname><given-names>SBG</given-names></name><name><surname>de Boer</surname><given-names>R</given-names></name><name><surname>Lim</surname><given-names>RT</given-names></name><name><surname>McPherson</surname><given-names>K</given-names></name><name><surname>Besra</surname><given-names>G</given-names></name><name><surname>Howell</surname><given-names>AR</given-names></name><name><surname>Moretta</surname><given-names>L</given-names></name><name><surname>McCluskey</surname><given-names>J</given-names></name><name><surname>Heemskerk</surname><given-names>MHM</given-names></name><name><surname>Gras</surname><given-names>S</given-names></name><name><surname>Rossjohn</surname><given-names>J</given-names></name><name><surname>Godfrey</surname><given-names>DI</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The molecular bases of δ/αβ T cell-mediated antigen recognition</article-title><source>The Journal of Experimental Medicine</source><volume>211</volume><fpage>2599</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1084/jem.20141764</pub-id><pub-id pub-id-type="pmid">25452463</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Mentzer</surname><given-names>AJ</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name><name><surname>Dong</surname><given-names>D</given-names></name><name><surname>Dejnirattisai</surname><given-names>W</given-names></name><name><surname>Rostron</surname><given-names>T</given-names></name><name><surname>Supasa</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>López-Camacho</surname><given-names>C</given-names></name><name><surname>Slon-Campos</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Stuart</surname><given-names>DI</given-names></name><name><surname>Paesen</surname><given-names>GC</given-names></name><name><surname>Grimes</surname><given-names>JM</given-names></name><name><surname>Antson</surname><given-names>AA</given-names></name><name><surname>Bayfield</surname><given-names>OW</given-names></name><name><surname>Hawkins</surname><given-names>D</given-names></name><name><surname>Ker</surname><given-names>DS</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Turtle</surname><given-names>L</given-names></name><name><surname>Subramaniam</surname><given-names>K</given-names></name><name><surname>Thomson</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Dold</surname><given-names>C</given-names></name><name><surname>Ratcliff</surname><given-names>J</given-names></name><name><surname>Simmonds</surname><given-names>P</given-names></name><name><surname>de Silva</surname><given-names>T</given-names></name><name><surname>Sopp</surname><given-names>P</given-names></name><name><surname>Wellington</surname><given-names>D</given-names></name><name><surname>Rajapaksa</surname><given-names>U</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Salio</surname><given-names>M</given-names></name><name><surname>Napolitani</surname><given-names>G</given-names></name><name><surname>Paes</surname><given-names>W</given-names></name><name><surname>Borrow</surname><given-names>P</given-names></name><name><surname>Kessler</surname><given-names>BM</given-names></name><name><surname>Fry</surname><given-names>JW</given-names></name><name><surname>Schwabe</surname><given-names>NF</given-names></name><name><surname>Semple</surname><given-names>MG</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name><name><surname>Moore</surname><given-names>SC</given-names></name><name><surname>Openshaw</surname><given-names>PJM</given-names></name><name><surname>Ansari</surname><given-names>MA</given-names></name><name><surname>Dunachie</surname><given-names>S</given-names></name><name><surname>Barnes</surname><given-names>E</given-names></name><name><surname>Frater</surname><given-names>J</given-names></name><name><surname>Kerr</surname><given-names>G</given-names></name><name><surname>Goulder</surname><given-names>P</given-names></name><name><surname>Lockett</surname><given-names>T</given-names></name><name><surname>Levin</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Jing</surname><given-names>R</given-names></name><name><surname>Ho</surname><given-names>LP</given-names></name><name><surname>Barnes</surname><given-names>E</given-names></name><name><surname>Dong</surname><given-names>D</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>Dunachie</surname><given-names>S</given-names></name><name><surname>Frater</surname><given-names>J</given-names></name><name><surname>Goulder</surname><given-names>P</given-names></name><name><surname>Kerr</surname><given-names>G</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>McMichael</surname><given-names>A</given-names></name><name><surname>Napolitani</surname><given-names>G</given-names></name><name><surname>Ogg</surname><given-names>G</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Salio</surname><given-names>M</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name><name><surname>Kenneth Baillie</surname><given-names>J</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Mentzer</surname><given-names>AJ</given-names></name><name><surname>Moore</surname><given-names>SC</given-names></name><name><surname>Openshaw</surname><given-names>PJM</given-names></name><name><surname>Semple</surname><given-names>MG</given-names></name><name><surname>Stuart</surname><given-names>DI</given-names></name><name><surname>Turtle</surname><given-names>L</given-names></name><name><surname>Cornall</surname><given-names>RJ</given-names></name><name><surname>Conlon</surname><given-names>CP</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Screaton</surname><given-names>GR</given-names></name><name><surname>Mongkolsapaya</surname><given-names>J</given-names></name><name><surname>McMichael</surname><given-names>A</given-names></name><name><surname>Knight</surname><given-names>JC</given-names></name><name><surname>Ogg</surname><given-names>G</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><collab>Oxford Immunology Network Covid-19 Response T cell Consortium</collab><collab>ISARIC4C Investigators</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Broad and strong memory CD4+ and CD8+ T cells induced by SARS-cov-2 in UK convalescent individuals following COVID-19</article-title><source>Nature Immunology</source><volume>21</volume><fpage>1336</fpage><lpage>1345</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-0782-6</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picelli</surname><given-names>S</given-names></name><name><surname>Björklund</surname><given-names>ÅK</given-names></name><name><surname>Faridani</surname><given-names>OR</given-names></name><name><surname>Sagasser</surname><given-names>S</given-names></name><name><surname>Winberg</surname><given-names>G</given-names></name><name><surname>Sandberg</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Smart-seq2 for sensitive full-length transcriptome profiling in single cells</article-title><source>Nature Methods</source><volume>10</volume><fpage>1096</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2639</pub-id><pub-id pub-id-type="pmid">24056875</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piepenbrink</surname><given-names>KH</given-names></name><name><surname>Blevins</surname><given-names>SJ</given-names></name><name><surname>Scott</surname><given-names>DR</given-names></name><name><surname>Baker</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The basis for limited specificity and MHC restriction in a T cell receptor interface</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>1948</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms2948</pub-id><pub-id pub-id-type="pmid">23736024</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Brenchley</surname><given-names>JM</given-names></name><name><surname>Ruff</surname><given-names>LE</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Hill</surname><given-names>BJ</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Migueles</surname><given-names>SA</given-names></name><name><surname>Gostick</surname><given-names>E</given-names></name><name><surname>Wooldridge</surname><given-names>L</given-names></name><name><surname>Sewell</surname><given-names>AK</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses</article-title><source>The Journal of Experimental Medicine</source><volume>202</volume><fpage>1349</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1084/jem.20051357</pub-id><pub-id pub-id-type="pmid">16287711</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="software"><person-group person-group-type="author"><collab>PyMOL</collab></person-group><year iso-8601-date="2015">2015</year><data-title>The pymol molecular graphics system</data-title><version designator="Version 1">Version 1</version><publisher-name>Schrödinger, LLC</publisher-name><ext-link ext-link-type="uri" xlink:href="https://pymol.org/2/">https://pymol.org/2/</ext-link></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redd</surname><given-names>AD</given-names></name><name><surname>Nardin</surname><given-names>A</given-names></name><name><surname>Kared</surname><given-names>H</given-names></name><name><surname>Bloch</surname><given-names>EM</given-names></name><name><surname>Abel</surname><given-names>B</given-names></name><name><surname>Pekosz</surname><given-names>A</given-names></name><name><surname>Laeyendecker</surname><given-names>O</given-names></name><name><surname>Fehlings</surname><given-names>M</given-names></name><name><surname>Quinn</surname><given-names>TC</given-names></name><name><surname>Tobian</surname><given-names>AAR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Minimal crossover between mutations associated with omicron variant of SARS-cov-2 and CD8+ T-cell epitopes identified in COVID-19 convalescent individuals</article-title><source>MBio</source><volume>13</volume><elocation-id>e0361721</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.03617-21</pub-id><pub-id pub-id-type="pmid">35229637</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riley</surname><given-names>TP</given-names></name><name><surname>Hellman</surname><given-names>LM</given-names></name><name><surname>Gee</surname><given-names>MH</given-names></name><name><surname>Mendoza</surname><given-names>JL</given-names></name><name><surname>Alonso</surname><given-names>JA</given-names></name><name><surname>Foley</surname><given-names>KC</given-names></name><name><surname>Nishimura</surname><given-names>MI</given-names></name><name><surname>Vander Kooi</surname><given-names>CW</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name><name><surname>Baker</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>T cell receptor cross-reactivity expanded by dramatic peptide-MHC adaptability</article-title><source>Nature Chemical Biology</source><volume>14</volume><fpage>934</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1038/s41589-018-0130-4</pub-id><pub-id pub-id-type="pmid">30224695</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roukens</surname><given-names>AHE</given-names></name><name><surname>Pothast</surname><given-names>CR</given-names></name><name><surname>König</surname><given-names>M</given-names></name><name><surname>Huisman</surname><given-names>W</given-names></name><name><surname>Dalebout</surname><given-names>T</given-names></name><name><surname>Tak</surname><given-names>T</given-names></name><name><surname>Azimi</surname><given-names>S</given-names></name><name><surname>Kruize</surname><given-names>Y</given-names></name><name><surname>Hagedoorn</surname><given-names>RS</given-names></name><name><surname>Zlei</surname><given-names>M</given-names></name><name><surname>Staal</surname><given-names>FJT</given-names></name><name><surname>de Bie</surname><given-names>FJ</given-names></name><name><surname>van Dongen</surname><given-names>JJM</given-names></name><name><surname>Arbous</surname><given-names>SM</given-names></name><name><surname>Zhang</surname><given-names>JLH</given-names></name><name><surname>Verheij</surname><given-names>M</given-names></name><name><surname>Prins</surname><given-names>C</given-names></name><name><surname>van der Does</surname><given-names>AM</given-names></name><name><surname>Hiemstra</surname><given-names>PS</given-names></name><name><surname>de Vries</surname><given-names>JJC</given-names></name><name><surname>Janse</surname><given-names>JJ</given-names></name><name><surname>Roestenberg</surname><given-names>M</given-names></name><name><surname>Myeni</surname><given-names>SK</given-names></name><name><surname>Kikkert</surname><given-names>M</given-names></name><name><surname>Yazdanbakhsh</surname><given-names>M</given-names></name><name><surname>Heemskerk</surname><given-names>MHM</given-names></name><name><surname>Smits</surname><given-names>HH</given-names></name><name><surname>Jochems</surname><given-names>SP</given-names></name><collab>in collaboration with BEAT-COVID group</collab><collab>in collaboration with COVID-19 LUMC group</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-cov-2-specific CD8+ T cell responses following COVID-19</article-title><source>Nature Immunology</source><volume>23</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01095-w</pub-id><pub-id pub-id-type="pmid">34937933</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rydyznski Moderbacher</surname><given-names>C</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Hastie</surname><given-names>KM</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Belanger</surname><given-names>S</given-names></name><name><surname>Abbott</surname><given-names>RK</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Crotty</surname><given-names>EG</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Rawlings</surname><given-names>SA</given-names></name><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>Tse</surname><given-names>LPV</given-names></name><name><surname>Frazier</surname><given-names>A</given-names></name><name><surname>Baric</surname><given-names>R</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Greenbaum</surname><given-names>J</given-names></name><name><surname>Ollmann Saphire</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antigen-specific adaptive immunity to SARS-cov-2 in acute COVID-19 and associations with age and disease severity</article-title><source>Cell</source><volume>183</volume><fpage>996</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.038</pub-id><pub-id pub-id-type="pmid">33010815</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salgado-Benvindo</surname><given-names>C</given-names></name><name><surname>Thaler</surname><given-names>M</given-names></name><name><surname>Tas</surname><given-names>A</given-names></name><name><surname>Ogando</surname><given-names>NS</given-names></name><name><surname>Bredenbeek</surname><given-names>PJ</given-names></name><name><surname>Ninaber</surname><given-names>DK</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hiemstra</surname><given-names>PS</given-names></name><name><surname>Snijder</surname><given-names>EJ</given-names></name><name><surname>van Hemert</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Suramin inhibits SARS-cov-2 infection in cell culture by interfering with early steps of the replication cycle</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>64</volume><elocation-id>e00900-20</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.00900-20</pub-id><pub-id pub-id-type="pmid">32513797</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schober</surname><given-names>K</given-names></name><name><surname>Buchholz</surname><given-names>VR</given-names></name><name><surname>Busch</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tcr repertoire evolution during maintenance of CMV-specific T-cell populations</article-title><source>Immunological Reviews</source><volume>283</volume><fpage>113</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1111/imr.12654</pub-id><pub-id pub-id-type="pmid">29664573</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekine</surname><given-names>T</given-names></name><name><surname>Perez-Potti</surname><given-names>A</given-names></name><name><surname>Rivera-Ballesteros</surname><given-names>O</given-names></name><name><surname>Strålin</surname><given-names>K</given-names></name><name><surname>Gorin</surname><given-names>JB</given-names></name><name><surname>Olsson</surname><given-names>A</given-names></name><name><surname>Llewellyn-Lacey</surname><given-names>S</given-names></name><name><surname>Kamal</surname><given-names>H</given-names></name><name><surname>Bogdanovic</surname><given-names>G</given-names></name><name><surname>Muschiol</surname><given-names>S</given-names></name><name><surname>Wullimann</surname><given-names>DJ</given-names></name><name><surname>Kammann</surname><given-names>T</given-names></name><name><surname>Emgård</surname><given-names>J</given-names></name><name><surname>Parrot</surname><given-names>T</given-names></name><name><surname>Folkesson</surname><given-names>E</given-names></name><name><surname>Rooyackers</surname><given-names>O</given-names></name><name><surname>Eriksson</surname><given-names>LI</given-names></name><name><surname>Henter</surname><given-names>JI</given-names></name><name><surname>Sönnerborg</surname><given-names>A</given-names></name><name><surname>Allander</surname><given-names>T</given-names></name><name><surname>Albert</surname><given-names>J</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name><name><surname>Klingström</surname><given-names>J</given-names></name><name><surname>Gredmark-Russ</surname><given-names>S</given-names></name><name><surname>Björkström</surname><given-names>NK</given-names></name><name><surname>Sandberg</surname><given-names>JK</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name><name><surname>Aleman</surname><given-names>S</given-names></name><name><surname>Buggert</surname><given-names>M</given-names></name><collab>Karolinska COVID-19 Study Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19</article-title><source>Cell</source><volume>183</volume><fpage>158</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.08.017</pub-id><pub-id pub-id-type="pmid">32979941</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Adaptive immunity to SARS-cov-2 and COVID-19</article-title><source>Cell</source><volume>184</volume><fpage>861</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.01.007</pub-id><pub-id pub-id-type="pmid">33497610</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shomuradova</surname><given-names>AS</given-names></name><name><surname>Vagida</surname><given-names>MS</given-names></name><name><surname>Sheetikov</surname><given-names>SA</given-names></name><name><surname>Zornikova</surname><given-names>KV</given-names></name><name><surname>Kiryukhin</surname><given-names>D</given-names></name><name><surname>Titov</surname><given-names>A</given-names></name><name><surname>Peshkova</surname><given-names>IO</given-names></name><name><surname>Khmelevskaya</surname><given-names>A</given-names></name><name><surname>Dianov</surname><given-names>DV</given-names></name><name><surname>Malasheva</surname><given-names>M</given-names></name><name><surname>Shmelev</surname><given-names>A</given-names></name><name><surname>Serdyuk</surname><given-names>Y</given-names></name><name><surname>Bagaev</surname><given-names>DV</given-names></name><name><surname>Pivnyuk</surname><given-names>A</given-names></name><name><surname>Shcherbinin</surname><given-names>DS</given-names></name><name><surname>Maleeva</surname><given-names>AV</given-names></name><name><surname>Shakirova</surname><given-names>NT</given-names></name><name><surname>Pilunov</surname><given-names>A</given-names></name><name><surname>Malko</surname><given-names>DB</given-names></name><name><surname>Khamaganova</surname><given-names>EG</given-names></name><name><surname>Biderman</surname><given-names>B</given-names></name><name><surname>Ivanov</surname><given-names>A</given-names></name><name><surname>Shugay</surname><given-names>M</given-names></name><name><surname>Efimov</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-cov-2 epitopes are recognized by a public and diverse repertoire of human T cell receptors</article-title><source>Immunity</source><volume>53</volume><fpage>1245</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.11.004</pub-id><pub-id pub-id-type="pmid">33326767</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiner</surname><given-names>S</given-names></name><name><surname>Schwarz</surname><given-names>T</given-names></name><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Sotzny</surname><given-names>F</given-names></name><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Volk</surname><given-names>HD</given-names></name><name><surname>Scheibenbogen</surname><given-names>C</given-names></name><name><surname>Hanitsch</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Reactive T cells in convalescent COVID-19 patients with negative SARS-cov-2 antibody serology</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>687449</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.687449</pub-id><pub-id pub-id-type="pmid">34322120</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stervbo</surname><given-names>U</given-names></name><name><surname>Rahmann</surname><given-names>S</given-names></name><name><surname>Roch</surname><given-names>T</given-names></name><name><surname>Westhoff</surname><given-names>TH</given-names></name><name><surname>Babel</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Epitope similarity can not explain the pre-formed T cell immunity towards structural SARS-cov-2 proteins</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>18995</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-75972-z</pub-id><pub-id pub-id-type="pmid">33149224</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>LF</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Antiviral memory phenotype T cells in unexposed adults</article-title><source>Immunological Reviews</source><volume>255</volume><fpage>95</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1111/imr.12095</pub-id><pub-id pub-id-type="pmid">23947350</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sylwester</surname><given-names>AW</given-names></name><name><surname>Mitchell</surname><given-names>BL</given-names></name><name><surname>Edgar</surname><given-names>JB</given-names></name><name><surname>Taormina</surname><given-names>C</given-names></name><name><surname>Pelte</surname><given-names>C</given-names></name><name><surname>Ruchti</surname><given-names>F</given-names></name><name><surname>Sleath</surname><given-names>PR</given-names></name><name><surname>Grabstein</surname><given-names>KH</given-names></name><name><surname>Hosken</surname><given-names>NA</given-names></name><name><surname>Kern</surname><given-names>F</given-names></name><name><surname>Nelson</surname><given-names>JA</given-names></name><name><surname>Picker</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects</article-title><source>The Journal of Experimental Medicine</source><volume>202</volume><fpage>673</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1084/jem.20050882</pub-id><pub-id pub-id-type="pmid">16147978</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szeto</surname><given-names>C</given-names></name><name><surname>Lobos</surname><given-names>CA</given-names></name><name><surname>Nguyen</surname><given-names>AT</given-names></name><name><surname>Gras</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tcr recognition of peptide-MHC-I: rule makers and breakers</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>E68</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22010068</pub-id><pub-id pub-id-type="pmid">33374673</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szomolay</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>PE</given-names></name><name><surname>Miles</surname><given-names>JJ</given-names></name><name><surname>Clement</surname><given-names>M</given-names></name><name><surname>Llewellyn-Lacey</surname><given-names>S</given-names></name><name><surname>Dolton</surname><given-names>G</given-names></name><name><surname>Ekeruche-Makinde</surname><given-names>J</given-names></name><name><surname>Lissina</surname><given-names>A</given-names></name><name><surname>Schauenburg</surname><given-names>AJ</given-names></name><name><surname>Sewell</surname><given-names>AK</given-names></name><name><surname>Burrows</surname><given-names>SR</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Wooldridge</surname><given-names>L</given-names></name><name><surname>van den Berg</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification of human viral protein-derived ligands recognized by individual MHCI-restricted T-cell receptors</article-title><source>Immunology and Cell Biology</source><volume>94</volume><fpage>573</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1038/icb.2016.12</pub-id><pub-id pub-id-type="pmid">26846725</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>AT</given-names></name><name><surname>Linster</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>CW</given-names></name><name><surname>Le Bert</surname><given-names>N</given-names></name><name><surname>Chia</surname><given-names>WN</given-names></name><name><surname>Kunasegaran</surname><given-names>K</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>Tham</surname><given-names>CYL</given-names></name><name><surname>Chia</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>GJD</given-names></name><name><surname>Young</surname><given-names>B</given-names></name><name><surname>Kalimuddin</surname><given-names>S</given-names></name><name><surname>Low</surname><given-names>JGH</given-names></name><name><surname>Lye</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>LF</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Early induction of functional SARS-cov-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients</article-title><source>Cell Reports</source><volume>34</volume><elocation-id>108728</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.108728</pub-id><pub-id pub-id-type="pmid">33516277</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>CCS</given-names></name><name><surname>Owen</surname><given-names>CJ</given-names></name><name><surname>Tham</surname><given-names>CYL</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name><name><surname>van Dorp</surname><given-names>L</given-names></name><name><surname>Balloux</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Pre-existing T cell-mediated cross-reactivity to SARS-cov-2 can not solely be explained by prior exposure to endemic human coronaviruses</article-title><source>Infection, Genetics and Evolution</source><volume>95</volume><elocation-id>105075</elocation-id><pub-id pub-id-type="doi">10.1016/j.meegid.2021.105075</pub-id><pub-id pub-id-type="pmid">34509646</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarke</surname><given-names>A</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Kidd</surname><given-names>CK</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Yu</surname><given-names>ED</given-names></name><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>da Silva Antunes</surname><given-names>R</given-names></name><name><surname>Moore</surname><given-names>E</given-names></name><name><surname>Rubiro</surname><given-names>P</given-names></name><name><surname>Methot</surname><given-names>N</given-names></name><name><surname>Phillips</surname><given-names>E</given-names></name><name><surname>Mallal</surname><given-names>S</given-names></name><name><surname>Frazier</surname><given-names>A</given-names></name><name><surname>Rawlings</surname><given-names>SA</given-names></name><name><surname>Greenbaum</surname><given-names>JA</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-cov-2 epitopes in COVID-19 cases</article-title><source>Cell Reports. Medicine</source><volume>2</volume><elocation-id>100204</elocation-id><pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100204</pub-id><pub-id pub-id-type="pmid">33521695</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarke</surname><given-names>A</given-names></name><name><surname>Coelho</surname><given-names>CH</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Yu</surname><given-names>ED</given-names></name><name><surname>Methot</surname><given-names>N</given-names></name><name><surname>Bloom</surname><given-names>NI</given-names></name><name><surname>Goodwin</surname><given-names>B</given-names></name><name><surname>Phillips</surname><given-names>E</given-names></name><name><surname>Mallal</surname><given-names>S</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Filaci</surname><given-names>G</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>da Silva Antunes</surname><given-names>R</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-cov-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron</article-title><source>Cell</source><volume>185</volume><fpage>847</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.01.015</pub-id><pub-id pub-id-type="pmid">35139340</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>S</given-names></name><name><surname>Kehl</surname><given-names>V</given-names></name><name><surname>Erber</surname><given-names>J</given-names></name><name><surname>Wagner</surname><given-names>KI</given-names></name><name><surname>Jetzlsperger</surname><given-names>AM</given-names></name><name><surname>Burrell</surname><given-names>T</given-names></name><name><surname>Schober</surname><given-names>K</given-names></name><name><surname>Schommers</surname><given-names>P</given-names></name><name><surname>Augustin</surname><given-names>M</given-names></name><name><surname>Crowell</surname><given-names>CS</given-names></name><name><surname>Gerhard</surname><given-names>M</given-names></name><name><surname>Winter</surname><given-names>C</given-names></name><name><surname>Moosmann</surname><given-names>A</given-names></name><name><surname>Spinner</surname><given-names>CD</given-names></name><name><surname>Protzer</surname><given-names>U</given-names></name><name><surname>Hoffmann</surname><given-names>D</given-names></name><name><surname>D’Ippolito</surname><given-names>E</given-names></name><name><surname>Busch</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cmv seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients</article-title><source>PLOS ONE</source><volume>17</volume><elocation-id>e0268530</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0268530</pub-id><pub-id pub-id-type="pmid">35613127</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Schmitz</surname><given-names>KS</given-names></name><name><surname>Raadsen</surname><given-names>MP</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Okba</surname><given-names>NMA</given-names></name><name><surname>Endeman</surname><given-names>H</given-names></name><name><surname>van den Akker</surname><given-names>JPC</given-names></name><name><surname>Molenkamp</surname><given-names>R</given-names></name><name><surname>Koopmans</surname><given-names>MPG</given-names></name><name><surname>van Gorp</surname><given-names>ECM</given-names></name><name><surname>Haagmans</surname><given-names>BL</given-names></name><name><surname>de Swart</surname><given-names>RL</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>de Vries</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Phenotype and kinetics of SARS-cov-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome</article-title><source>Science Immunology</source><volume>5</volume><elocation-id>48</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abd2071</pub-id><pub-id pub-id-type="pmid">32591408</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wooldridge</surname><given-names>L</given-names></name><name><surname>Laugel</surname><given-names>B</given-names></name><name><surname>Ekeruche</surname><given-names>J</given-names></name><name><surname>Clement</surname><given-names>M</given-names></name><name><surname>van den Berg</surname><given-names>HA</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Sewell</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cd8 controls T cell cross-reactivity</article-title><source>Journal of Immunology</source><volume>185</volume><fpage>4625</fpage><lpage>4632</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1001480</pub-id><pub-id pub-id-type="pmid">20844204</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wooldridge</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Individual MHCI-restricted T-cell receptors are characterized by a unique peptide recognition signature</article-title><source>Frontiers in Immunology</source><volume>4</volume><elocation-id>199</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2013.00199</pub-id><pub-id pub-id-type="pmid">23888160</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuhair</surname><given-names>M</given-names></name><name><surname>Smit</surname><given-names>GSA</given-names></name><name><surname>Wallis</surname><given-names>G</given-names></name><name><surname>Jabbar</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Devleesschauwer</surname><given-names>B</given-names></name><name><surname>Griffiths</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis</article-title><source>Reviews in Medical Virology</source><volume>29</volume><elocation-id>e2034</elocation-id><pub-id pub-id-type="doi">10.1002/rmv.2034</pub-id><pub-id pub-id-type="pmid">30706584</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82050.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Belz</surname><given-names>Gabrielle T</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rqy9422</institution-id><institution>University of Queensland</institution></institution-wrap><country>Australia</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.07.31.502203" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.07.31.502203"/></front-stub><body><p>This study examines the possibility that high incidence of SARS-CoV2 reactive T cells occur in apparently COVID 19 naive individuals. The study sheds new light on how unrelated virus-specific T cells might be involved in generating immunity to SARS-CoV-2 and is an elegantly performed study.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82050.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Belz</surname><given-names>Gabrielle T</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rqy9422</institution-id><institution>University of Queensland</institution></institution-wrap><country>Australia</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.07.31.502203">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.07.31.502203v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses can originate from cross-reactive CMV-specific T cells&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Satyajit Rath as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Clarification of experimental explanations as guided by the reviewers (esp related to Reviewer 3).</p><p>2) Improvement of clarity of language/expression (esp related to Reviewer 2).</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>This is a very nice story.</p><p>Multiple potential epitopes were examined in SARS-COV2 while in CMV, only the most immunogenic antigen, pp65, was examined. The rationale for this selection is not entirely clear.</p><p>The presence of IPS/FVS cross-reactive T cells were examined in severe COVID patients. The patient cohort is very small and while 2/2 patients showed evidence of these cells, it is difficult to interpret given the limited dataset. Has this feature been examined in a larger cohort of patients?</p><p>Figures: The data in a number of the flow cytometry plots is almost impossible to read given the very small font size. The figures would be enhanced by increasing the font size of all percentages of the populations of interest.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Abstract: it should be made clear that the crossreactive T cells reduced viral spreading at lower MOIs.</p><p>Introduction, line 55: there are now some papers showing that mutations can result in T-cell escape so it would be good to reference these for completion.</p><p>Introduction, line 60: it may read better if this sentence read as follows: 'This finding indicates that T cells which were initially primed against other pathogens are able to cross-recognize SARS-CoV-2 antigen'.</p><p>Introduction, line 63: The sentence which starts 'Highly homologous…..' would benefit from editing as it is confusing to use the word 'sequences' twice without specifying whether this refers to DNA, RNA, peptides etc…</p><p>Introduction, line 78: suggest changing 'a potential trigger' to 'the initial trigger'.</p><p>Introduction, line 84: suggest using 'trigger' instead of 'potential source'.</p><p>Introduction, line 88: can you clarify the previously proposed role for these cross-reactive T cells?</p><p>Introduction, line 89: change 'indicated' into 'indicate', change 'COVID-19' into 'COVID-19 immunity'.</p><p>Introduction, line 91: change 'Taking' into 'Taken'.</p><p>Introduction, line 91-92: suggest deleting 'a memory response against CMV' and replacing with 'the CMV specific memory population'.</p><p>Introduction, line 98: suggest changing 'in' to 'presented by'.</p><p>Introduction, line 108: suggest changing the end of the sentence to 'preventing SARS-CoV-2 infection or reducing the severity of COVID-19'.</p><p>Results, line 123: the text states that no marked increase in CD4 T cell responses were observed after stimulation with spike in CMV+ donors. However, Figure 1C shows 3 circles depicting a CD4 T cell response to S in CMV+ donors. Please check if this is correct and alter either the text or figure accordingly.</p><p>Results, line 124: the text states that 7 CMV+ donors showed CD4 T cell responses to M. However, only three circles are visible in Figure 1C depicting CD4 T cell responses against M in CMV+ donors. Please check is this correct and if necessary correct figure or text accordingly.</p><p>Results, line: 174: need to provide an explanation for how the pp65 mapping described in Figure S2B was performed e.g. what do the H and V peptide pools refer to?</p><p>Results, line 180: why does the membrane protein epitope identity remain unidentified?</p><p>Results, general comment: it would be good to clarify why a different approach to CMV epitope mapping was taken for CD4 versus CD8 T cells?</p><p>Results, line 229: clarify how these two residues are similar.</p><p>Results, line 278: clarify how it is possible to tetramer sort cells if they are below the background level.</p><p>Results, line 321: need to state 'MOI of 0.05' at the end of this sentence.</p><p>Data generated using acute infection samples: more details need to be provided for these samples (e.g. some basic information such as age, gender, time post PCR+ test, symptoms etc.). The text states that IPS/FVS specific T cells showed lower expression of CD38 and HLA-DR than IPS specific T cells. This seems to be true for donor CHZ but not for donor KDH – please check and edit as necessary. As only two samples were studied then these data should not be overinterpreted e.g. unless more donors are added to this analysis then I would not suggest referring to these data in the abstract. I would also consider deleting or editing the end of the sentence at the end of the first paragraph in the Discussion section.</p><p>Methods</p><p>Line 472: include more details of the S, S1 and S+ pools used in this study.</p><p>Figures</p><p>Figure 1A: would be good to label this so that it is clear that it refers to CD4 T cells.</p><p>Figure 1B: would be good to label this so that it is clear that it refers to CD8 T cells.</p><p>Figure 1C and 1E: some stats comparing CMV+ versus CMV- donors might be useful here (either in the figure or in the legend).</p><p>Figure 2A and B: please check stats here as I would usually expect this test to be used for multiple repeats using the same clone (rather than differing numbers of repeats with different clones).</p><p>Figure 5, legend, line 344: was does 'were taken along' mean?</p><p>Figure 5, legend, line 344: insert 'at' before '24'.</p><p>Figure 5, legend, line 349: which peptide pool was used here?</p><p>Supp Figures</p><p>Supp Figure 3: change label showing the CPL data to panel 'D'.</p><p>Supp Figure 3E: why are there different affinity values shown for peptides IPSINVHHY and LEQIKTHWL?</p><p>Supp Figure 4: make it clear in the title of this figure that this is structural modelling.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82050.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>This is a very nice story.</p><p>Multiple potential epitopes were examined in SARS-COV2 while in CMV, only the most immunogenic antigen, pp65, was examined. The rationale for this selection is not entirely clear.</p></disp-quote><p>The main aim of the experiments displayed in figure 1 was to identify SARS-CoV-2-specific T cells in CMV seropositive and seronegative donors. We therefore focused on a broader SARS-CoV-2 peptide pool repertoire to facilitate detection of cross-reactive T cells. Pp65 was added to the experiment to confirm that the CMV seropositive donors had developed CMV-specific T cells. We understand that it was unclear why pp65 only was tested, therefore we have clarified this in the manuscript (line 124-126).</p><disp-quote content-type="editor-comment"><p>The presence of IPS/FVS cross-reactive T cells were examined in severe COVID patients. The patient cohort is very small and while 2/2 patients showed evidence of these cells, it is difficult to interpret given the limited dataset. Has this feature been examined in a larger cohort of patients?</p></disp-quote><p>We agree that 2 patients is limiting and ideally the cohort would include more patients. Unfortunately, we had several inclusion criteria that complicated the search for suitable samples (1) Patients had to be HLA typed which is expensive and therefore not routinely performed, (2) If HLA was known, the donor had to be HLA-B*35:01, (3) the donor had to be CMV seropositive, (4) sampling should have been performed during acute disease, (5) patient should not receive immunosuppressive treatment during or prior to sampling which is a common treatment (prednisolone and dexamethasone) for severe COVID-19. As a consequence, suitable samples to study the role of the IPS/FVS-specific T cells are, unfortunately, scarce.</p><disp-quote content-type="editor-comment"><p>Figures: The data in a number of the flow cytometry plots is almost impossible to read given the very small font size. The figures would be enhanced by increasing the font size of all percentages of the populations of interest.</p></disp-quote><p>We apologize for the inconvenience, the percentages are now in larger font size or deleted when not relevant.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Abstract: it should be made clear that the crossreactive T cells reduced viral spreading at lower MOIs.</p></disp-quote><p>We agree that the abstract should accurately describe the conclusions in the specific context of the study. The sentence has been completely removed following the comments by the other reviewers and our own views after re-evaluating the abstract (line 37-39).</p><disp-quote content-type="editor-comment"><p>Introduction, line 55: there are now some papers showing that mutations can result in T-cell escape so it would be good to reference these for completion.</p></disp-quote><p>The majority of the literature investigating this subject describes that the T cell response is minimally affected by mutations found in the current variants of concern, whilst antibodies are affected.[1-9] We therefore believe that the sentence in the original manuscript is still in line with the consensus of the current data. To update the introduction, we added “or vaccination” (line 55) and cited new literature (lines 55-58).</p><disp-quote content-type="editor-comment"><p>Introduction, line 60: it may read better if this sentence read as follows: 'This finding indicates that T cells which were initially primed against other pathogens are able to cross-recognize SARS-CoV-2 antigen'.</p></disp-quote><p>Thank you for this suggestion, this has been adapted in the manuscript (lines 62-63).</p><disp-quote content-type="editor-comment"><p>Introduction, line 63: The sentence which starts 'Highly homologous…..' would benefit from editing as it is confusing to use the word 'sequences' twice without specifying whether this refers to DNA, RNA, peptides etc…</p></disp-quote><p>Thank you for this suggestion, this has been adapted in the manuscript (lines 64-65).</p><disp-quote content-type="editor-comment"><p>Introduction, line 78: suggest changing 'a potential trigger' to 'the initial trigger'.</p></disp-quote><p>Thank you for this suggestion, this has been adapted in the manuscript (line 80).</p><disp-quote content-type="editor-comment"><p>Introduction, line 84: suggest using 'trigger' instead of 'potential source'.</p></disp-quote><p>Thank you for this suggestion, this has been adapted in the manuscript (line 86).</p><disp-quote content-type="editor-comment"><p>Introduction, line 88: can you clarify the previously proposed role for these cross-reactive T cells?</p></disp-quote><p>We removed part of the sentence as we see that it was a confusing sentence (lines 90-91). The role of cross-reactive T cells is not clear yet. Lines 88-90 describe an association between CMV and cross-reactive T cells with COVID-19. Lines 92-93 describe the current consensus on the role for cross-reactive T cells.</p><disp-quote content-type="editor-comment"><p>Introduction, line 89: change 'indicated' into 'indicate', change 'COVID-19' into 'COVID-19 immunity'.</p></disp-quote><p>Thank you for this suggestion, this has been adapted in the manuscript (line 92).</p><disp-quote content-type="editor-comment"><p>Introduction, line 91: change 'Taking' into 'Taken'.</p></disp-quote><p>Thank you for this suggestion, this has been adapted in the manuscript (line 94).</p><disp-quote content-type="editor-comment"><p>Introduction, line 91-92: suggest deleting 'a memory response against CMV' and replacing with 'the CMV specific memory population'.</p></disp-quote><p>Thank you for this suggestion, this has been adapted in the manuscript (lines 95).</p><disp-quote content-type="editor-comment"><p>Introduction, line 98: suggest changing 'in' to 'presented by'.</p></disp-quote><p>Thank you for this suggestion, this has been adapted in the manuscript (line 101 and 102).</p><disp-quote content-type="editor-comment"><p>Introduction, line 108: suggest changing the end of the sentence to 'preventing SARS-CoV-2 infection or reducing the severity of COVID-19'.</p></disp-quote><p>Thank you for this suggestion, this has been adapted in the manuscript (lines 112).</p><disp-quote content-type="editor-comment"><p>Results, line 123: the text states that no marked increase in CD4 T cell responses were observed after stimulation with spike in CMV+ donors. However, Figure 1C shows 3 circles depicting a CD4 T cell response to S in CMV+ donors. Please check if this is correct and alter either the text or figure accordingly.</p></disp-quote><p>There was a mistake in the figure, it has been adapted in the new manuscript version (Figure 1C).</p><disp-quote content-type="editor-comment"><p>Results, line 124: the text states that 7 CMV+ donors showed CD4 T cell responses to M. However, only three circles are visible in Figure 1C depicting CD4 T cell responses against M in CMV+ donors. Please check is this correct and if necessary correct figure or text accordingly.</p></disp-quote><p>There was a mistake in the figure and text which has been adapted in the new manuscript version (Figure 1C and line 131).</p><disp-quote content-type="editor-comment"><p>Results, line: 174: need to provide an explanation for how the pp65 mapping described in Figure S2B was performed e.g. what do the H and V peptide pools refer to?</p></disp-quote><p>The method has been elaborated in the figure legend (figure S2B, Lines 1057-1058), material and methods (lines 572-576) and Results section (line 184-185).</p><disp-quote content-type="editor-comment"><p>Results, line 180: why does the membrane protein epitope identity remain unidentified?</p></disp-quote><p>We aimed to identify the membrane protein epitope by separately ordering the 15-mers as peptide library, high pH Reversed Phase HPLC fragmentation of the membrane peptide pool, and <italic>in silico</italic> prediction based on sequence similarity to the CMV pp65 epitope AGILARNLVPM. Unfortunately, none of these methods resulted in identification of the epitope. We speculate that the epitope has hydrophobic characteristics, as usually found in membrane peptides, thereby complicating synthesis (also suggested by the manufacturer) and handling. We agree that this should be explained in the text, since it is currently unclear whether we attempted to identify the epitope (line 191-192).</p><disp-quote content-type="editor-comment"><p>Results, general comment: it would be good to clarify why a different approach to CMV epitope mapping was taken for CD4 versus CD8 T cells?</p></disp-quote><p>The CPL assay is commonly used to identify the epitope of CD8<sup>+</sup> T cell clones. However, for CD4<sup>+</sup> T cells this is not the case since the CPL assay often results in recognition patterns which are too complex to interpret. This is due to complicating factors which are typical for TCRs found in CD4<sup>+</sup> T cells, such as variable epitope lengths and varying overhanging amino acids. Therefore, we decided to take an hypothesis-driven approach to identify the epitope. We clarified the use of CPL assay in lines 205-206.</p><disp-quote content-type="editor-comment"><p>Results, line 229: clarify how these two residues are similar.</p></disp-quote><p>This has been clarified in the manuscript (line 249-250).</p><disp-quote content-type="editor-comment"><p>Results, line 278: clarify how it is possible to tetramer sort cells if they are below the background level.</p></disp-quote><p>For tetramer+ T cells that are measurable, but below background level, it is unclear whether these events are background or whether it is a true but small population. This was the case for JZX in figure 1C. For flow cytometry analysis (Figure 3C) 1-2x10<sup>6</sup> PBMCs were used whilst for sorting 10-50 fold more PBMCs (45x10<sup>6</sup> PBMCs in case of JZX) were first enriched using magnetic activated cell sorting (MACS) followed by flow activated cell sorting (FACS). This reduced the background level and increases the purity of tetramer+ cells which can also be observed in the clonality of the TCR sequencing in figure 4a. This has been clarified in line 310, and in material and methods lines 603 and 611.</p><disp-quote content-type="editor-comment"><p>Results, line 321: need to state 'MOI of 0.05' at the end of this sentence.</p></disp-quote><p>This has been added to the manuscript (lines 358-359).</p><disp-quote content-type="editor-comment"><p>Data generated using acute infection samples: more details need to be provided for these samples (e.g. some basic information such as age, gender, time post PCR+ test, symptoms etc.). The text states that IPS/FVS specific T cells showed lower expression of CD38 and HLA-DR than IPS specific T cells. This seems to be true for donor CHZ but not for donor KDH – please check and edit as necessary. As only two samples were studied then these data should not be overinterpreted e.g. unless more donors are added to this analysis then I would not suggest referring to these data in the abstract. I would also consider deleting or editing the end of the sentence at the end of the first paragraph in the Discussion section.</p></disp-quote><p>a) Indications that these patients suffered from critical disease was indeed lacking. We added the WHO classification and additional information in table S1. We do not have time post PCR+ test, but we did include time post symptom onset and ICU admission.</p><p>b) This conclusion was indeed not in line with the figure and also not the main message from the figure. We have adapted this as it is more important to note that FVS/IPS-specific T cells are not more activated than IPS-specific T cells (line 369).</p><p>c) We agree with this comment and lines 37-39 have been removed and line 414 adapted.</p><disp-quote content-type="editor-comment"><p>Methods</p><p>Line 472: include more details of the S, S1 and S+ pools used in this study.</p></disp-quote><p>This has been clarified in lines 123 and 529-531.</p><disp-quote content-type="editor-comment"><p>Figures</p><p>Figure 1A: would be good to label this so that it is clear that it refers to CD4 T cells.</p></disp-quote><p>Has been adapted in manuscript to improve understanding of the figure at first glance.</p><disp-quote content-type="editor-comment"><p>Figure 1B: would be good to label this so that it is clear that it refers to CD8 T cells.</p></disp-quote><p>Has been adapted in manuscript to improve understanding of the figure at first glance.</p><disp-quote content-type="editor-comment"><p>Figure 1C and 1E: some stats comparing CMV+ versus CMV- donors might be useful here (either in the figure or in the legend).</p></disp-quote><p>The figure was mainly focused on descriptive statistics: do we see SARS-CoV-2 specific T cells in CMV-seropositive donors that are not present in CMV-seronegative donors. Membrane-specific CD4<sup>+</sup> T cell responses were not significantly increased in CMV+ compared to CMV- (Mann-Whitney <italic>U</italic>-test, data did not pass normality tests). Which is also what we would expect, since these 2-6 responses are more regarded as “outliers” by the test. Therefore, we cannot claim that there is a cohort-wide correlation (we show there is a mechanistic correlation) between CMV seropositivity and membrane-specific CD4<sup>+</sup> T cells, since only 6 responses were detected.</p><disp-quote content-type="editor-comment"><p>Figure 2A and B: please check stats here as I would usually expect this test to be used for multiple repeats using the same clone (rather than differing numbers of repeats with different clones).</p></disp-quote><p>The data points were displayed this way to be transparent regarding the number of experimental repeats. However, we understand that this is an uncommon way to show the data. The figure has been adapted by plotting the mean of the experimental replicates per clone and then a paired t-test was performed to test significance. The number of experimental repeats are depicted in the figure legend.</p><disp-quote content-type="editor-comment"><p>Figure 5, legend, line 344: was does 'were taken along' mean?</p></disp-quote><p>This has been clarified in the manuscript (lines 384-385).</p><disp-quote content-type="editor-comment"><p>Figure 5, legend, line 344: insert 'at' before '24'.</p></disp-quote><p>This has been modified in the manuscript (line 388).</p><disp-quote content-type="editor-comment"><p>Figure 5, legend, line 349: which peptide pool was used here?</p></disp-quote><p>This has been clarified in the manuscript (line 391).</p><disp-quote content-type="editor-comment"><p>Supp Figures</p><p>Supp Figure 3: change label showing the CPL data to panel 'D'.</p></disp-quote><p>This has been corrected in the manuscript.</p><disp-quote content-type="editor-comment"><p>Supp Figure 3E: why are there different affinity values shown for peptides IPSINVHHY and LEQIKTHWL?</p></disp-quote><p>This was a copy-paste mistake from two different tables. It has been corrected.</p><disp-quote content-type="editor-comment"><p>Supp Figure 4: make it clear in the title of this figure that this is structural modelling.</p></disp-quote><p>This has been adapted in the manuscript (lines 262 and 264).</p><p>References</p><p>1. Jung, M.K., et al., BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality. Nature Microbiology, 2022. 7(6): p. 909-917.</p><p>2. Tarke, A., et al., SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Α to Omicron. Cell, 2022.</p><p>3. Keeton, R., et al., T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature, 2022.</p><p>4. Gao, Y., et al., Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat Med, 2022.</p><p>5. Choi, S.J., et al., T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant. Cell Mol Immunol, 2022. 19(3): p. 447-448.</p><p>6. Redd, A.D., et al., Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8(+) T-Cell Epitopes Identified in COVID-19 Convalescent Individuals. mBio, 2022. 13(2): p. e0361721.</p><p>7. Liu, J., et al., Vaccines Elicit Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron. Nature, 2022.</p><p>8. Chiuppesi, F., et al., Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Δ and Omicron variants. iScience, 2022. 25(8): p. 104745.</p><p>9. GeurtsvanKessel, C.H., et al., Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients. Sci Immunol, 2022: p. eabo2202.</p></body></sub-article></article>